Professor Robert Simes

Director,, NHMRC Clinical Trials Centre
Medicine, Sydney Medical School
NHMRC Clinical Trials Centre

Telephone +61 2 9562 5000
Fax +61 2 9565 1863

Map

Biographical details

Professor John Simes is Director of the National Health and Medical Research Council (NHMRC) Clinical Trials Centre based at the University of Sydney. He is a Senior Principal Research Fellow of the NHMRC. He is also a practising medical oncologist at the Royal Prince Alfred Hospital and lectures in Clinical Epidemiology, in the School of Public Health and Community Medicine at the University of Sydney. His teaching interests are in controlled trials, trials methodology and clinical decision making. His research interests include clinical trials design and methodology, quality of life assessment, cancer and cardiovascular trials and methods for combining evidence from several trials aimed at improving clinical practice.

Selected grants

2015

  • Phase III trial of Concurrent & Adjuvant Temozolomide chemotherapy in non-1p/19q deleted anaplastic glioma; Nowak A, Simes R; Cancer Australia/Priority Driven Collaborative Cancer Research Scheme.

2014

  • Grey Matters - National Brain Cancer Biobanking Consortium Project - Cooperative Trials Group for Neuro-Oncology (COGNO); Simes R; Cancer Council New South Wales/Seed Funding.
  • National Brain Cancer Biobanking Consortium; Simes R; Roche Products Pty Limited/Research Grant.
  • ASCOLT: Aspirin for Dukes C and High Risk Dukes B Colorectal Cancers. An International, Multi-centre, Double Blind, Randomised Trial; Segelov E, Simes R, Tebbutt N, Zalcberg J, Sommeijer D, Chia J; Cancer Australia/Priority Driven Collaborative Cancer Research Scheme.

2013

  • PETACC-6: Preoperative chemoradiotherapy and postoperative chemotherapy with capecitabine and oxaliplatin vs. capecitabine alone in locally advanced rectal cancer; Price T, Harvey J, Simes R, Zalcberg J, Karapetis C, Tebbutt N; Cancer Australia/Priority Driven Collaborative Cancer Research Scheme.
  • PETACC-6: Preoperative chemoradiotherapy and postoperative chemotherapy with capecitabine and oxaliplatin vs. capecitabine alone in locally advanced rectal cancer; Price T, Harvey J, Tebbutt N, Simes R, Zalcberg J, Karapetis C; Cancer Council New South Wales/Research Project Grants.
  • The biological basis of success or failure to the anti-VEGF agent, bevacizumab in patients with recurrent glioblastoma; Simes R, McDonald K, Brown C, Yip S; Cancer Council New South Wales/Research Project Grants.
  • Improving patient outcomes for patients with Gastrointestinal (GI) cancer through clinical trials research: An application on behalf of the Australasian Gastro-Intestinal Trials Group (AGITG); Goldstein D, Simes R, Abdi E, Ackland S, Pavlakis N, Shannon J; Cancer Institute New South Wales/Cooperative Clinical Trial (CCT) Grants.
  • Advancing the evidence base for care and policy in priority health areas; Simes R, Keech A, Gebski V, Stockler M, Caterson I, Colagiuri S, Schofield D, Marschner C; National Health and Medical Research Council (NHMRC)/Program Grants.
  • COGNO infrastructure funding for support, development and conduct of clinical trials and translational research; Hovey E, Simes R, Koh E, Agar M, McDonald K, Wheeler H; Cancer Institute New South Wales/Cooperative Clinical Trial (CCT) Grants.

2012

  • Centre of Research Excellence for Translational Breast Cancer Research: From Discovery to Better Health Outcomes; Lindeman G, Mann B, Desai J, Forbes J, Fox S, Liew D, McArthur G, Simes R, Sutherland R, Visvader J; National Health and Medical Research Council (NHMRC)/Centres of Research Excellence.
  • Evaluation of a web-based tool for estimating and explaining prognosis in advanced cancer; Kiely B, Stockler M, Butow P, Tattersall M, Simes R; Cancer Australia/Priority Driven Collaborative Cancer Research Scheme.
  • Biomarker for Cardiovascular Risk Assessment in Europe (BiomarCaRE); Blankenberg S, Kuulasmaa K, Salomaa V, Breek H, Pasterkamp G, Hofer I, Illig T, Peters A, Koenig W, Weinberger K, Ziegler A, Siebert U, Schnell-Inderst P, Wollert K, Dent A, Bogaard P, Werner E, Wild P, Munzel T, Njolstad I, Mathiesen E, Zeller T, Schnabel R, Biasucci L, Iacoviello L, Crea F, Volzke H, Felix S, Bobak M, Kee F, Dallongeville J, Sans S, Wiklund P, Metspalu A, Jorgensen T, Ferrario M, Tunstall-Pedoe H, Muller C, Rothenbacher D, Konig W, Ridker P, Simes R, Tonkin A, Anand S; European Commission (Belgium)/Seventh Framework Network of Excellence Programme.
  • GeneAtlas Personal Microarray System; Richardson D, Scolyer R, Stocker R, Weninger W, Black J, Allen D, Murray M, Mason R, Twigg S, King N, Horvath L, Lovicu F, Lee C, Halliday G, Lovejoy D, Joshua D, Sharland A, Roufogalis B, Hambly B, Morris B, Bao B, Bishop A, Hibbs D, Lane D, Zhou F, Hanrahan J, Dixon K, Rendina L, Byrne M, Naylor M, Cole N, Jansson P, Dong Q, Codd R, Payne R, Assinder S, Chadban S, Fraser S, McLennan S, Suryo Rahmanto A, Lai D, Yu Y, Ju Y, Buckland M, Kovacevic Z, Saletta F, Zreiqat H, Kalinowski D, Groundwater P, Simes R, Zhang D, Boyer M, Murphy C; National Health and Medical Research Council (NHMRC)/Equipment Grants.
  • Phase III trial of Concurrent & Adjuvant Temozolomide chemotherapy in non-1p/19q deleted anaplastic glioma; Nowak A, Rosenthal M, Simes R, Ryan G, Drummond K; Cancer Australia/Priority Driven Collaborative Cancer Research Scheme.
  • Senior Principal Research Fellowship; Simes R; National Health and Medical Research Council (NHMRC)/Career Awards: Australian Fellowship.
  • Pathogenesis and risk assessment of coronary artery disease; Simes R, Kirby A, Meikle P; National Health and Medical Research Council (NHMRC)/Project Grants.
  • Maintain the National Clinical Trials Register, 01/04/2012 - 31/12/2016; Simes R, Askie L; National Health and Medical Research Council (NHMRC)/Enabling Grants.

2011

  • Translating Health Discovery Superscience; Askie L, Simes R; Therapeutic Innovation Australia Limited/Infrastructure Grant.
  • Sydney Catalyst: the Translational Cancer Research Centre of Central Sydney and Regional NSW.; Simes R; Cancer Institute New South Wales/Translational Health Services Research Grant.

2010

  • NHMRC Clinical Trials Centre, University of Sydney and the Centre for Biostatistics and Clinical Trials, Peter MacCallum Cancer Centre CCTDU; Simes R; Cancer Australia/Support for Cancer Clinical Trials - Existing National Cooperative Oncology groups.

2009

  • Temporary account for NHMRC CTC funds; Simes R; Commonwealth Department of Health and Ageing/Research Grant.
  • Development and operational support for ALTG, ANZUP and GOGNO through the NHMRC Clinical Trials Centre: A NSW-led initiative; Stockler M, Simes R, Grimison P, Hague W; Cancer Institute New South Wales/Clinical Trials Infrastructure Grants.
  • Biostatistics, quality assurance and data systems for cancer trial groups activities based at the NHMRC Clinical Trials Centre; Gebski V, Simes R, Hague W, Gainford M, Stockler M, Goldstein D, Friedlander M, Grimison P; Cancer Institute New South Wales/Clinical Trials Infrastructure Grants.
  • Development and operational support for AGITG and ANZGOG through the NHMRC Clinical Trials Centre: A NSW-led initiative; Simes R, Friedlander M, Goldstein D, Gainford M; Cancer Institute New South Wales/Clinical Trials Infrastructure Grants.
  • An international randomised trial of low-dose aspirin to prevent recurrent venous thromboembolism (INSPIRE); Ockelford P, Brighton T, Eikelboom J, Simes R, Gallus A, Agnelli G, Kakkar A, Ockleford P, Xavier D, Hague W, Mister R; National Health and Medical Research Council (NHMRC)/Project Grants.
  • Temporary account for NHMRC CTC funds; Simes R; Department of Health and Ageing (Federal)/Research Support.
  • Temporary account for NHMRC CTC funds; Simes R; Department of Health and Ageing (Federal)/Research Support.

2008

  • Cancer Clinical Trials Development Unit; Simes R, Fisher R, Salkeld G, Ackland S; Cancer Australia/Support for Cancer Clinical Trials.
  • Cooperative Trials Group for Neuro-Oncology (COGNO); Rosenthal M, Simes R; Cancer Australia/Support for Cancer Clinical Trials.
  • Clinical trials advances for better health outcomes; Simes R, Keech A, Gebski V, Stockler M; National Health and Medical Research Council (NHMRC)/Project Grants.
  • Australasian Gastro-Intestinal trials Group; Simes R; Cancer Australia/Support for Cancer Clinical Trials - Existing National Cooperative Oncology groups.
  • Preop chemoradiotherapy&postop chemo with capeciabine&oxaliplatin vs capecitabine alone in locally a; Price T, Harvey J, Tebbutt N, Hruby G, Bydder S, Simes R, Zalcberg J; Cancer Australia/Priority Driven Collaborative Cancer Research Scheme.

2007

  • NHMRC - Research Fellowship; Simes R; National Health and Medical Research Council (NHMRC)/Established Career Fellowships.

2006

  • Nhmrc Clinical Trials Centre Clinical Trials Methodology And Practice Consultancy, Incorporating Utilisation And Enhancement Of A Web-Based Electronic Clinical Trials Data Management System And Repository; Simes R, Keech A, Gebski V, Hague W, Stockler M; National Health and Medical Research Council (NHMRC)/Enabling Grants.
  • ASPIRE Study to prevent recurrent venous thromboembolism (VTE); Ehle D, Simes R; Health Research Council of New Zealand (NZ)/BLO Project.
  • Australian Clinical Trials Registry; Simes R; National Health and Medical Research Council (NHMRC)/Enabling Grants.
  • FIELD substudies, research and analysis.; Keech A, Simes R; Laboratoires Fournier/Research grant.

2005

  • Establishment, maintenance and operation of The Australian Clinical Trials Registry; Wood L, Askie L, Simes R; Bayer/Project Support.
  • Sentinal node biopsy versus axillary clearence in breast cancer: the SNAC trial; Stockler M, Gebski V, Simes R; National Breast Cancer Foundation/Kathleen Cuningham Research Grant.
  • Intermediate and high risk localized, completely resected, gastrointestinal stromal tumors (GIST) expressing c-KIT receptor: a controlled randomised trial on adjuvant Imatinib mesylate (�Glivec�), versus no further therapy after complete surgery; Zalcberg J, Yip S, Therasse P, Simes R, Lynch K, Conley R; Australian Gastro-Intestinal Trials Group (AGITG)/Research Grants.
  • LIPID and LIPID Cohort Studies (BMS); Simes R, Hague W, Keech A; Bristol Myers Squibb/Research Grant.
  • Not known; Simes R; Astra/Gastroenterological Soc/Research Grant.
  • Intermediate and high risk resected gastro-intestinal stromal tumours expressing kit: RCT of adjuvant mesylate; Simes R, Zalcberg J, Mann B, Smithers B, Kotasek D, Waring P, Van Hazel G; Cancer Council New South Wales/Research Project Grants.
  • Agreement for the provision of funding to enable the development of an interim clinical trials registry; Ghersi D, Simes R, Goldstein D, Nutt M; National Health and Medical Research Council (NHMRC)/Research Support.
  • NHF Lipid Trial; Simes R; National Heart Foundation/Default scheme.
  • Clinical trials operations and statistical services grant; Simes R; Cancer Institute New South Wales/Research Grant.
  • Infrastructure support for the AGITG and ANZGOG through the NHMRC Clinical Trials Centre - A NSW led initiative; Simes R, Stockler M; Cancer Institute New South Wales/Research Grant.

2004

  • ASPIRE Study to prevent recurrent venous thromboembolism (VTE) - Bayer; Simes R; Bayer/Research Grants.
  • A phase III randomised study of Cetuximab(Erbitux C225) and best supportive care vs. supportive care in patients with pre-treated metastatic epidermal growth factor receptor (EGEFR)- postive colorectal carcinoma.; Conley R, Sigal E, Simes R; Bristol Myers Squibb/Research Grants.
  • A randomised phase II study evaluating a weekly schedule of Docetaxel (Taxotere R) with cisplatin and 5-FU (wTCF) or with Capecitabine (Xeloda R) (wTX) in advanced oesophago-gastric cancer.; Conley R, Simes R, Stockler M; Aventis Pharma P/L & Aust Gastro Intestinal Trials Group/BLO Project.
  • Not Known - To be advised; Simes R; AGITG/AGITG Trials.
  • ASPIRE Study to prevent recurrent venous thromboembolism (VTE) - NSW Health; Simes R; NSW Department of Health/Research Grant.
  • Low-dose aspirin to prevent venous thromboembolism (ASPIRE) study: a multicentre randomised trial; Eikelboom J, Brighton T, Baker R, Rodgers A, Simes R, Brighton T, Baker R; National Health and Medical Research Council (NHMRC)/Project Grants.

2003

  • Australian-based cochrane collaboration activities - COLLABORATIVE Review Group with editorial base in Australia; Ghersi D, Simes R; DHA/Cochrane Collaborative Groups Funding Scheme.
  • Advances in clinical trials research and evidence-based decision making; Marschner C, Stockler M, Keech A, Simes R, Gebski V; National Health and Medical Research Council (NHMRC)/Program Grants.
  • ANZGOG #02-01 A phase II trial of weekly docetaxel (taxetere) for patients with relapsed ovarian cancer who have previously received paclitaxel; Simes R, Hannah C, Burrell K; Aventis Pharma P/L & Aust Gastro Intestinal Trials Group/BLO Project.

2002

  • Clinical medicine and science; Simes R; National Health and Medical Research Council (NHMRC)/Established Career Fellowships.
  • Cochrane Breast Cancer Group; Simes R; DHA/Cochrane Collaborative Groups Funding Scheme.
  • Patient preferences for adjuvant chemotherapy for early breast cancer: what makes it worthwhile?; Stockler M, Simes R, Coates A, Francis P, Reaby L; National Health and Medical Research Council (NHMRC)/Project Grants.
  • NHMRC Clinical Trials Centre; Simes R, Keech A; National Health and Medical Research Council (NHMRC)/Centre of Clinical Research Excellence.

2001

  • NHMRC-CTC support of GOG and ANZGOTG Gynaecologic Oncology Clinical Trials research agreement between the University of Sydney and the American College of Obstetricians and Gynecologists; Yip S, Sharp M, Simes R, Friedlander M; American College of Obstetricians and Gynecologists/BLO Project.
  • Antidepressants and subjective well-being in advanced cancer: a double-blind randomised trial of Sertraline and St Johns Wort; Stockler M, Wilcken N, Simes R; Cancer Council New South Wales/Research Project Grants.

2000

  • Provision of assessment and research related services on medical technologies and procedures for the Medical Services Advisory Committee (MSAC); Simes R, Eckermann S, Keech A, Irwig L, Ghersi D, Stockler M, Gebski V, Eckermann S, Lord S, Howard K, Salkeld G; Department of Health and Ageing (Federal)/Research Support.
  • Breast Cancer Clinical Trials Group; Simes R; ANZ Breast Cancer Trials Group/Project Grants.
  • The HERO-2 study.; Simes R, Keech A; The Medicines Company (USA)/Project Grant.
  • National Breast Cancer Centre: Cochrane review group; Simes R, Ghersi D; Cancer Council New South Wales/National Breast Cancer Centre Grant.
  • Coordinated program of clinical trials research; Simes R, Ackland S, Bell D; Cancer Council New South Wales/Infrastructure Development Grant.
  • AGITG; Simes R; Australasian Gastro-intestinal Trials Group/Medical Research Funds.
  • Lipid BMS; Simes R; Heart Foundation of Australia/Medical Research Funds.
  • Fournier Clinical Trial - Finland; Simes R; Laboratories Fournier (France)/Research Support.
  • Lipid study; Simes R; Heart Foundation of Australia/Medical Research Funds.
  • Symphony; Keech A, Simes R; The Cleveland Clinic Foundation/Contract Research.
  • An open prospective randomised comparison of hirulog versus heparin in patients receiving aspirin and thrombolysis (Streptokinase) for the treatment of AMI; Simes R; The Medicines Company (USA)/Research Support.
  • Clinical trials unit (1997); Simes R; National Health and Medical Research Council (NHMRC)/Program, Unit, Centre, and Institute Grants.
  • Lipid C-E study; Simes R, Hall J, Glasziou P; Heart Foundation of Australia/Medical Research Funds.
  • Systematic reviews of randomised controlled trials of chemotherapy and endocrine therapy in advanced breast cancer; Simes R, Henderson I, Brunswick C, Ghersi D; US Army Medical Research Acquisition Group/Breast Cancer Research Program Grant.

1999

  • Research entitled Paragon B between the University of Sydney and Duke University and Hoffman-La Roche, Inc.; Spear L, Simes R; Duke University (USA)/BLO Project.

Selected publications

Download citations: PDF RTF Endnote

Book Chapters

  • Gebski, V., Keech, A., Simes, R. (2007). Applying subgroup analysis to individual patient decisions. In Anthony Keech, Val Gebski, Rhana Pike (Eds.), Interpreting and reporting clinical trials: a guide to the CONSORT statement and the principles of randomised controlled trials, (pp. 114-122). Sydney: AMPCo.

Journals

  • Simes, R., Becattini, C., Agnelli, G., Eikelboom, J., Kirby, A., Mister, R., Prandoni, P., Brighton, T. (2014). Aspirin for the Prevention of Recurrent Venous Thromboembolism: The INSPIRE Collaboration. Circulation (Baltimore), 130(13), 1062-1071. [More Information]
  • White, H., Tonkin, A., Simes, R., Stewart, R., Mann, K., Thompson, P., Colquhoun, D., West, M., Nestel, P., Sullivan, D., Keech, A., et al (2014). Association of Contemporary Sensitive Troponin I Levels at Baseline and Change at 1 Year With Long - Term Coronary Events Following Myocardial Infarction or Unstable Angina. Journal of the American College of Cardiology, 63(4), 345-354. [More Information]
  • Jonker, D., Karapetis, C., Harbison, C., O’Callaghan, C., Tu, D., Simes, R., Malone, D., Langer, C., Tebbutt, N., Price, T., et al (2014). Epiregulin gene expression as a biomarker of benefit from cetuximab in the treatment of advanced colorectal cancer. British Journal of Cancer, 110(3), 648-655. [More Information]
  • Funke-Kaiser, A., Mann, K., Colquhoun, D., Zeller, T., Hunt, D., Simes, R., Sullivan, D., Sydow, K., West, M., White, H., et al (2014). Midregional proadrenomedullin and its change predicts recurrent major coronary events and heart failure in stable coronary heart disease patients: the LIPID study. International Journal of Cardiology, 172(2), 411-418. [More Information]
  • Chen, J., Hovey, E., Rosenthal, M., Ratcliffe, A., Simes, R. (2014). Neuro-oncology practices in Australia: A Cooperative Group for Neuro-Oncology patterns of care study. Asia-Pacific Journal of Clinical Oncology, 10(2), 162-167. [More Information]
  • Karapetis, C., Jonker, D., Daneshmand, M., Hanson, J., OCallghan, C., Marginean, C., Zalcberg, J., Simes, R., Moore, M., Tebbutt, N., et al (2014). PIK3CA, BRAF, and PTEN Status and Benefit from Cetuximab in the Treatment of Advanced Colorectal Cancer--Results from NCIC CTG/AGITG CO.17. Clinical Cancer Research, 20(3), 744-753. [More Information]
  • White, H., Tonkin, A., Simes, R., Stewart, R., Mann, K. (2014). Reply to Letter to the Editor: Troponin I to target treatments which reduce cardiovascular risk - while waiting for Godot. Journal of the American College of Cardiology, 636(25), 2876-2886.
  • Hudson, H., Lo, S., Simes, R., Tonkin, A., Heritier, S. (2014). Semiparametric methods for multistate survival models in randomised trials. Statistics in Medicine, 33, 1621-1645. [More Information]
  • Carter, H., Zannino, D., Simes, R., Schofield, D., Howard, K., Zalcberg, J., Price, T., Tebbutt, N. (2014). The cost effectiveness of bevacizumab when added to capecitabine, with or without mitomycin-C, in first line treatment of metastatic colorectal cancer: Results from the Australasian phase III MAX study. European Journal of Cancer, 50(3), 535-543. [More Information]
  • Glasziou, P., Irwig, L., Kirby, A., Tonkin, A., Simes, R. (2014). Which lipid measurement should we monitor? An analysis of the LIPID study. BMJ Open, 4(2), e003512. [More Information]
  • Simes, R., Winship, I., McNeil, J. (2013). A funding model for public-good clinical trials. Medical Journal of Australia, 199(2), 90-91. [More Information]
  • Lee, C., Simes, R., Brown, C., Gebski, V., Pfisterer, J., Swart, A., Berton-Rigaud, D., Plante, M., Skeie-Jensen, T., Vergote, I., Lord, S., et al (2013). A prognostic nomogram to predict overall survival in patients with platinum-sensitive recurrent ovarian cancer. Annals of Oncology, 24(4), 937-943. [More Information]
  • Simes, R., Eikelboom, J., Brighton, T. (2013). Aspirin for preventing venous thromboembolism. The New England Journal of Medicine, 368(8), 773. [More Information]
  • Vickers, M., Karapetis, C., Tu, D., O'Callaghan, C., Price, T., Tebbutt, N., van Hazel, G., Shapiro, J., Pavlakis, N., Gibbs, P., Simes, R., et al (2013). Association of hypomagnesemia with inferior survival in a phase III, randomized study of cetuximab plus best supportive care versus best supportive care alone: NCIC CTG/AGITG CO.17. Annals of Oncology, 24(4), 953-960. [More Information]
  • White, H., Simes, R., Stewart, R., Blankenberg, S., Barnes, E., Marschner, C., Thompson, P., West, M., Zeller, T., Colquhoun, D., Keech, A., Sullivan, D., et al (2013). Changes in lipoprotein-associated phospholipase A2 activity predict coronary events and partly account for the treatment effect of pravastatin: results from the Long-Term Intervention with Pravastatin in Ischemic Disease study. Journal of the American Heart Association, 2(5), 1-12. [More Information]
  • Stenson, B., Tarnow-Mordi, W., Darlow, B., Simes, R., Juszczak, E., Askie, L., Battin, M., Bowler, U., Broadbent, R., Cairns, P., Donoghoe, M., Ghadge, A., Hague, W., Kirby, A., et al (2013). Oxygen Saturation and Outcomes in Preterm Infants. The New England Journal of Medicine, 368(22), 2094-2104. [More Information]
  • Siu, L., Shapiro, J., Jonker, D., Karapetis, C., Zalcberg, J., Simes, R., Couture, F., Moore, M., Price, T., Siddiqui, J., et al (2013). Phase III Randomized, Placebo-Controlled Study of Cetuximab Plus Brivanib Alaninate Versus Cetuximab Plus Placebo in PatientsWith Metastatic, Chemotherapy-Refractory, Wild-TypeK-RASColorectal Carcinoma: The NCIC Clinical Trials Group and AGITG CO.20 Trial. Journal of Clinical Oncology, 31(19), 2477-2484. [More Information]
  • Nestel, P., Barnes, E., Tonkin, A., Simes, R., Fournier, M., White, H., Colquhoun, D., Blankenberg, S., Sullivan, D. (2013). Plasma Lipoprotein(a) Concentration Predicts Future Coronary and Cardiovascular Events in Patients With Stable Coronary Heart Disease. Arteriosclerosis, Thrombosis, and Vascular Biology, 33(12), 2902-2908. [More Information]
  • Price, T., Hardingham, J., Lee, C., Townsend, A., Wrin, J., Wilson, K., Weickhardt, A., Simes, R., Murone, C., Tebbutt, N. (2013). Prognostic impact and the relevance of PTEN copy number alterations in patients with advanced colorectal cancer (CRC) receiving bevacizumab. Cancer Medicine, 2(3), 277-285. [More Information]
  • Martin, A., Simes, R. (2013). Quality-adjusted survival as an end point in breast cancer trials. Clinical Investigation, 3(6), 545-555. [More Information]
  • Anderson, C., Heeley, E., Huang, Y., Wang, J., Stapf, C., Delcourt, C., Lindley, R., Robinson, T., Lavados, P., Neal, B., Hata, J., Arima, H., Heritier, S., Li, Q., Woodward, M., Simes, R., Chalmers, J., et al (2013). Rapid Blood-Pressure Lowering in Patients with Acute Intracerebral Hemorrhage. The New England Journal of Medicine, 368(25), 2355-2365. [More Information]
  • Tarnow-Mordi, W., Simes, R., Cruz, M. (2013). Strategies to accelerate recruitment to NHMRC multi-centre clinical trials. Journal of Paediatrics and Child Health, 49(1), e103-e105. [More Information]
  • Simes, R., Webb, S. (2013). Sustaining Australian research through clinical trials and investigator networks. Medical Journal of Australia, 198(3), 127-128. [More Information]
  • Lee, C., Gebski, V., Coates, A., Veillard, A., Harvey, V., Tattersall, M., Byrne, M., Brigham, B., Forbes, J., Simes, R. (2013). Trade-offs in quality of life and survival with chemotherapy for advanced breast cancer: mature results of a randomized trial comparing single-agent mitoxantrone with combination cyclophosphamide, methotrexate, 5-fluorouracil and prednisone. SpringerPlus, 2(391), 1-10. [More Information]
  • Boekholdt, S., Arsenault, B., Mora, S., Pedersen, T., LaRosa, J., Nestel, P., Simes, R., Durrington, P., Hitman, G., Welch, K., et al (2012). Association of LDL cholesterol, non-HDL cholesterol, and apolipoprotein B levels with risk of cardiovascular events among patients treated with statins: a meta-analysis. JAMA: The Journal of the American Medical Association, 307(12), 1302-1309. [More Information]
  • Ting, R., Keech, A., Drury, P., Donoghoe, M., Hedley, J., Jenkins, A., Davis, T., Lehto, S., Celermajer, D., Simes, R., Rajamani, K., et al (2012). Benefits and Safety of Long-Term Fenofibrate Therapy in People With Type 2 Diabetes and Renal Impairment - The FIELD Study. Diabetes Care, 35(2), 218-225. [More Information]
  • Price, T., Zannino, D., Wilson, C., Simes, R., Cassidy, J., Van Hazel, G., Robinson, B., Broad, A., Ganju, V., Ackland, S., Tebbutt, N. (2012). Bevacizumab is equally effective and no more toxic in elderly patients with advanced colorectal cancer: a subgroup analysis from the AGITG MAX trial: an international randomised controlled trial of Capecitabine, Bevacizumab and Mitomycin C. Annals of Oncology, 23(6), 1531-1536. [More Information]
  • Verry, H., Lord, S., Martin, A., Gill, G., Lee, C., Howard, K., Wetzig, N., Simes, R. (2012). Effectiveness and cost-effectiveness of sentinel lymph node biopsy compared with axillary node dissection in patients with early-stage breast cancer: a decision model analysis. British Journal of Cancer, 106(6), 1045-1052. [More Information]
  • Tonkin, A., Hunt, D., Voysey, M., Kesaniemi, Y., Hamer, A., Waites, J., Mahar, L., Mann, S., Glasziou, P., Forder, P., Simes, R., Keech, A. (2012). Effects of fenofibrate on cardiovascular events in patients with diabetes, with and without prior cardiovascular disease: The Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study. American Heart Journal, 163(3), 508-514. [More Information]
  • Dear, R., Barratt, A., Evans, A., Simes, R., Newsom, J., Kent, D., Crossing, S., Holliday, C., Segelov, E., Hruby, G., Tattersall, M. (2012). Identifying and prioritising gaps in colorectal cancer trials research in Australia. Medical Journal of Australia, 197(9), 507-511. [More Information]
  • Lee, C., Marschner, C., Simes, R., Voysey, M., Egleston, B., Hudes, G., de Souza, P. (2012). Increase in Cholesterol PredictsSsurvival Advantage in Renal Cell Carcinoma Patients Treated with Temsirolimus. Clinical Cancer Research, 18(11), 3188-3196. [More Information]
  • Emberson, J., Kearney, P., Blackwell, L., Newman, C., Reith, C., Bhala, N., Holland, L., Peto, R., Keech, A., Collins, R., Simes, R., et al (2012). Lack of effect of lowering LDL cholesterol on cancer: meta-analysis of individual data from 175 000 people in 27 randomised trials of statin therapy. PloS One, 7(1), 1-10. [More Information]
  • Staub, L., Dyer, S., Lord, S., Simes, R. (2012). Linking the evidence: intermediate outcomes in medical test assessments. International Journal of Technology Assessment in Health Care, 28(1), 52-58. [More Information]
  • Brighton, T., Eikelboom, J., Mann, K., Mister, R., Gallus, A., Ockelford, P., Gibbs, H., Hague, W., Xavier, D., Diaz, R., Kirby, A., Simes, R. (2012). Low-Dose Aspirin for Preventing Recurrent Venous Thromboembolism. The New England Journal of Medicine, 367(2), 1979-1987. [More Information]
  • Mihaylova, B., Emberson, J., Blackwell, L., Keech, A., Simes, R., Barnes, E., Voysey, M., Gray, A., Collins, R., Baigent, C., et al (2012). The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials. The Lancet, 380(9841), 581-590. [More Information]
  • Keech, A., Simes, R., Fulcher, J. (2012). The role of statin therapy in patients with lower vascular risk. Medical Journal of Australia, 197(3), 130-131. [More Information]
  • Staub, L., Lord, S., Simes, R., Dyer, S., Houssami, N., Chen, R., Irwig, L. (2012). Using patient management as a surrogate for patient health outcomes in diagnostic test evaluation. BMC Medical Research Methodology, 12, 1-12. [More Information]
  • Lee, C., Hudson, M., Stockler, M., Coates, A., Ackland, S., Gebski, V., Lord, S., Friedlander, M., Boyle, F., Simes, R. (2011). A nomogram to predict survival time in women starting first-line chemotherapy for advanced breast cancer. Breast Cancer Research and Treatment, 129(2), 467-476. [More Information]
  • Sullivan, D., Forder, P., Simes, R., Whiting, M., Kritharides, L., Merrifield, A., Donoghoe, M., Colman, P., Neil, G., Haapamäki, H., Keech, A. (2011). Associations between the use of metformin, sulphonylureas, or diet alone and cardiovascular outcomes in 6005 patients with type 2 diabetes in the FIELD study. Diabetes Research and Clinical Practice, 94(2), 284-290. [More Information]
  • Stockler, M., Harvey, V., Francis, P., Byrne, M., Ackland, S., Fitzharris, B., Van Hazel, G., Wilcken, N., Grimison, P., Nowak, A., Zannino, D., Gebski, V., Coates, A., et al (2011). Capecitabine Versus Classical Cyclophosphamide, Methotrexate, and Fluorouracil As First-Line Chemotherapy for Advanced Breast Cancer. Journal of Clinical Oncology, 29(34), 4498-4504. [More Information]
  • Lee, C., Gurney, H., Brown, C., Sorio, R., Donadello, N., Tulunay, G., Meier, W., Bacon, M., Maenpaa, J., Petru, E., Gebski, V., Lord, S., Simes, R., et al (2011). Carboplatin–paclitaxel-induced leukopenia and neuropathy predict progression-free survival in recurrent ovarian cancer. British Journal of Cancer, 105(3), 360-365. [More Information]
  • Lee, C., Friedlander, M., Brown, C., Gebski, V., Georgoulopoulos, A., Vergote, I., Pignata, S., Donadello, N., Schmalfeldt, B., Delva, R., Lord, S., Simes, R., et al (2011). Early Decline in Cancer Antigen 125 as a Surrogate for Progression-Free Survival in Recurrent Ovarian Cancer. Journal of the National Cancer Institute, 103(17), 1338-1342. [More Information]
  • Davis, T., Ting, R., Best, J., Donoghoe, M., Drury, P., Sullivan, D., Jenkins, A., O'Connell, R., Whiting, M., Glasziou, P., Simes, R., Gebski, V., Keech, A., et al (2011). Effects of fenofibrate on renal function in patients with type 2 diabetes mellitus: the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) Study. Diabetologia, 54(2), 280-290. [More Information]
  • Goel, S., Simes, R., Beith, J. (2011). Exploratory analysis of cardiac biomarkers in women with normal cardiac function receiving trastuzumab for breast cancer. Asia-Pacific Journal of Clinical Oncology, 7(3), 276-280. [More Information]
  • de Boer, S., Barnes, E., Westerhout, C., Simes, J., Granger, C., Kastrati, A., Widimsky, P., de Boer, M., Zijlstra, F., Boersma, E. (2011). High-risk patients with ST-elevation myocardial infarction derive greatest absolute benefit from primary percutaneous coronary intervention: Results from the Primary Coronary Angioplasty Trialist versus Thrombolysis (PCAT)-2 Collaboration. American Heart Journal, 161(3), 500-507.e1. [More Information]
  • Dear, R., Barratt, A., McGeechan, K., Askie, L., Simes, R., Tattersall, M. (2011). Landscape of cancer clinical trials in Australia: using trial registries to guide future research. Medical Journal of Australia, 194(8), 387-391. [More Information]
  • Simes, R. (2011). Medical Oncology Group of Australia Cancer Achievement Award - Inspirations and influences for a life in clinical trials. Cancer Forum, 35(1), 48-50.
  • Ananda, S., Nowak, A., Cher, L., Dowling, A., Brown, C., Simes, R., Rosenthal, M. (2011). Phase 2 trial of temozolomide and pegylated liposomal doxorubicin in the treatment of patients with glioblastoma multiforme following concurrent radiotherapy and chemotherapy. Journal of Clinical Neuroscience, 18(11), 1444-1448. [More Information]
  • Lee, C., Simes, R., Brown, C., Lord, S., Wagner, U., Plante, M., Vergote, I., Pisano, C., Parma, G., Burges, A., Gebski, V., et al (2011). Prognostic nomogram to predict progression-free survival in patients with platinum-sensitive recurrent ovarian cancer. British Journal of Cancer, 105(8), 1144-1150. [More Information]
  • Cox, K., Goel, S., O'Connell, R., Boyer, M., Beale, P., Simes, R., Stockler, M. (2011). Randomized cross-over trial comparing inpatient and outpatient administration of high-dose cisplatin. Internal Medicine Journal, 41(2), 172-178. [More Information]
  • Tebbutt, N., Murphy, F., Zannino, D., Wilson, C., Cummins, M., Abdi, E., Strickland, A., Lowenthal, R., Marx, G., Karapetis, C., Shannon, J., Simes, R., et al (2011). Risk of arterial thromboembolic events in patients with advanced colorectal cancer receiving bevacizumab. Annals of Oncology, 22(8), 1834-1838. [More Information]
  • Farrar, D., Duley, L., Burls, A., Dorling, J., Embleton, N., McGuire, W., Oddie, S., Simes, R., Tarnow-Mordi, W., Thornton, J., et al (2011). Rushing to clamp umbilical cord: More evidence is needed to inform practice. BMJ: British Medical Journal, 342(Letters), d122-d122. [More Information]
  • Clarke, S., Yip, S., Brown, C., van Hazel, G., Ransom, D., Goldstein, D., Jeffrey, G., Tebbutt, N., Buck, M., Lowenthal, R., Boland, A., Gebski, V., Simes, R., et al (2011). Single-agent irinotecan or 5-fluorouracil and leucovorin (FOLFIRI) as second-line chemotherapy for advanced colorectal cancer; results of a randomised phase II study (DaVINCI) and meta-analysis. European Journal of Cancer, 47(12), 1826-1836. [More Information]
  • Sjoquist, K., Burmeister, B., Smithers, B., Zalcberg, J., Simes, R., Barbour, A., Gebski, V. (2011). Survival after neoadjuvant chemotherapy or chemoradiotherapy for resectable oesophageal carcinoma: an updated meta-analysis. The Lancet Oncology, 12(7), 681-692. [More Information]
  • Simes, R., Voysey, M., O'Connell, R., Glasziou, P., Best, J., Scott, R., Pardy, C., Byth Wilson, K., Sullivan, D., Ehnholm, C., Keech, A. (2010). A novel method to adjust efficacy estimates for uptake of other active treatments in long-term clinical trials. PloS One, 5(1), e8580-1-e8580-10. [More Information]
  • Taskinen, M., Barter, P., Ehnholm, C., Sullivan, D., Mann, K., Simes, R., Best, J., Hamwood, S., Keech, A. (2010). Ability of traditional lipid ratios and apolipoprotein ratios to predict cardiovascular risk in people with type 2 diabetes. Diabetologia, 53(9), 1846-1855. [More Information]
  • De Roock, W., Jonker, D., Di Nicolantonio, F., Sartore-Bianchi, A., Tu, D., Siena, S., Lamba, S., Arena, S., Frattini, M., Piessevaux, H., Simes, R., et al (2010). Association of KRAS p.G13D Mutation With Outcome in Patients With Chemotherapy-Refractory Metastatic Colorectal Cancer Treated With Cetuximab. JAMA: The Journal of the American Medical Association, 304(16), 1812-1820. [More Information]
  • Tebbutt, N., Wilson, K., Gebski, V., Cummins, M., Zannino, D., van Hazel, G., Robinson, B., Broad, A., Ganju, V., Ackland, S., Stockler, M., Simes, R., et al (2010). Capecitabine, Bevacizumab and Mitomycin in First-Line Treatment of Metastatic Colorectal Cancer: Results of the Australasian Gastrointestinal Trials Group Randomized, Phase III MAX Study. Journal of Clinical Oncology, 28(19), 3191-3198. [More Information]
  • Van Glabbeke, M., Verweij, J., Blay, J., Debiec-Rychter, M., Demetri, G., Heinrich, M., Borden, E., Blanke, C., Crowley, J., Rankin, C., Zalcberg, J., Simes, R., et al (2010). Comparison of Two Doses of Imatinib for the Treatment of Unresectable or Metastatic Gastrointestinal Stromal Tumors: A Meta-Analysis of 1,640 Patients. Journal of Clinical Oncology, 28(7), 1247-1253. [More Information]
  • Grimison, P., Stockler, M., Thomson, D., Olver, I., Harvey, V., Gebski, V., Lewis, C., Levi, J., Boyer, M., Gurney, H., Boland, A., Simes, R., et al (2010). Comparison of Two Standard Chemotherapy Regimens for Good-Prognosis Germ Cell Tumors: Updated Analysis of a Randomized Trial. Journal of the National Cancer Institute, 102(16), 1253-1262. [More Information]
  • Davis, T., Ting, R., Best, J., Donoghoe, M., Drury, P., Sullivan, D., Jenkins, A., O'Connell, R., Whiting, M., Glasziou, P., Simes, R., Gebski, V., Keech, A., et al (2010). Effects of fenofibrate on renal function in patients with type 2 diabetes mellitus: the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) Study. Diabetologia, 54(2), 280-290. [More Information]
  • Baigent, C., Blackwell, L., Emberson, J., Holland, L., Reith, C., Bhala, N., Peto, R., Barnes, E., Keech, A., Simes, R., et al (2010). Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170 000 participants in 26 randomised trials. The Lancet, 376(9753), 1670-1681. [More Information]
  • Lee, C., Lord, S., Stockler, M., Coates, A., Gebski, V., Simes, R. (2010). Historical cross-trial comparisons for competing treatments in advanced breast cancer - An empirical analysis of bias. European Journal of Cancer, 46(3), 541-548. [More Information]
  • de Boer, S., Westerhout, C., Simes, R., Granger, C., Zijlstra, F., Boersma, E. (2010). Mortality and Morbidity Reduction by Primary Percutaneous Coronary Intervention Is Independent of the Patient's Age. J A C C: Cardiovascular Interventions, 3(3), 324-331. [More Information]
  • Lee, C., Stockler, M., Coates, A., Gebski, V., Lord, S., Simes, R. (2010). Self-reported health-related quality of life is an independent predictor of chemotherapy treatment benefit and toxicity in women with advanced breast cancer. British Journal of Cancer, 102(9), 1341-1347. [More Information]
  • Cui, J., Forbes, A., Kirby, A., Marschner, C., Simes, R., Hunt, D., West, M., Tonkin, A. (2010). Semi-parametric risk prediction models for recurrent cardiovascular events in the LIPID study. BMC Medical Research Methodology, 10(27), 27-1-27-9. [More Information]
  • Askie, L., Baur, L., Campbell, K., Daniels, L., Hesketh, K., Magarey, A., Mihrshahi, S., Rissel, C., Simes, R., Taylor, B., Voysey, M., et al (2010). The Early Prevention of Obesity in CHildren (EPOCH) Collaboration - an Individual Patient Data Prospective Meta-Analysis. BMC Public Health, 10, 728-1-728-8. [More Information]
  • Califf, R., Armstrong, P., Granger, C., Harrington, R., Lee, K., Simes, R., van de Werf, F., Wallentin, L., White, H. (2010). Towards a new order in cardiovascular medicine: re-engineering through global collaboration. European Heart Journal, 31(8), 911-917. [More Information]
  • Simes, R., O'Connell, R., Aylward, P., Varshavsky, S., Diaz, R., Wilcox, R., Armstrong, P., Granger, C., French, J., Van de Werf, F., Marschner, C., et al (2010). Unexplained international differences in clinical outcomes after acute myocardial infarction and fibrinolytic therapy: Lessons from the Hirulog and Early Reperfusion or Occlusion (HERO)-2 trial. American Heart Journal, 159(6), 988-997. [More Information]
  • Grimison, P., Simes, R., Hudson, M., Stockler, M. (2009). Deriving a Patient-Based Utility Index from a Cancer-Specific Quality of Life Questionnaire. Value in Health, 12(5), 800-807. [More Information]
  • Cui, J., Forbes, A., Kirby, A., Simes, R., Tonkin, A. (2009). Laboratory and non-laboratory-based risk prediction models for secondary prevention of cardiovascular disease: the LIPID study. European Journal of Cardiovascular Prevention and Rehabilitation, 16(6), 660-668. [More Information]
  • Soderberg, S., Colquhoun, D., Keech, A., Yallop, J., Barnes, E., Pollicino, C., Simes, R., Tonkin, A., Nestel, P. (2009). Leptin, but not adiponectin, is a predictor of recurrent cardiovascular events in men: results from the LIPID study. International Journal of Obesity, 33(1), 123-130. [More Information]
  • Lee, C., Lord, S., Coates, A., Simes, R. (2009). Molecular biomarkers to individualise treatment: assessing the evidence. Medical Journal of Australia, 190(11), 631-636. [More Information]
  • Grimison, P., Simes, R., Hudson, M., Stockler, M. (2009). Preliminary Validation of an Optimally Weighted Patient-Based Utility Index by Application to Randomized Trials in Breast Cancer. Value in Health, 12(6), 967-976. [More Information]
  • Mittman, N., Au, H., Tu, D., O'Callaghan, C., Isogai, P., Karapetis, C., Zalcberg, J., Evans, W., Moore, M., Siddiqui, J., Simes, R., Tebbutt, N., et al (2009). Prospective Cost-Effectiveness Analysis of Cetuximab in Metastatic Colorectal Cancer: Evaluation of National Cancer Institute of Canada Clinical Trials Group CO.17 Trial. Journal of the National Cancer Institute, 101(17), 1182-1192. [More Information]
  • Taskinen, M., Sullivan, D., Ehnholm, C., Whiting, M., Zannino, D., Simes, R., Keech, A., Barter, P. (2009). Relationships of HDL cholesterol, ApoA-I, and ApoA-II with homocysteine and creatinine in patients with Type 2 diabetes treated with fenofibrate. Arteriosclerosis, Thrombosis, and Vascular Biology, 29(6), 950-955. [More Information]
  • Gill, G., Wetzig, N., Gebski, V., Stockler, M., Ung, O., Campbell, I., Simes, R. (2009). Sentinel-Lymph-Node-Based Management or Routine Axillary Clearance? One-Year Outcomes of Sentinel Node Biopsy Versus Axillary Clearance (SNAC): A Randomized Controlled Surgical Trial. Annals of Surgical Oncology, 16(2), 266-275. [More Information]
  • Berger, J., Elliott, L., Gallup, D., Roe, M., Granger, C., Armstrong, P., Simes, R., White, H., Van de Werf, F., Topol, E., et al (2009). Sex Differences in Mortality Following Acute Coronary Syndromes. JAMA: The Journal of the American Medical Association, 302(8), 874-882. [More Information]
  • Carrick, S., Parker, S., Thornton, C., Ghersi, D., Simes, R., Wilcken, N. (2009). Single agent versus combination chemotherapy for metastatic breast cancer. Cochrane Database of Systematic Reviews, (2), CD003372-1-CD003372-109. [More Information]
  • Clarke, P., Hayes, A., Glasziou, P., Scott, R., Simes, R., Keech, A. (2009). Using the EQ-5D index score as a predictor of outcomes in patients with type 2 diabetes. Medical Care, 47(1), 61-68. [More Information]
  • Hayes, A., Clarke, P., Glasziou, P., Simes, R., Drury, P., Keech, A. (2008). Can self-rated health scores be used for risk prediction in patients with type 2 diabetes? Diabetes Care, 31(4), 795-797. [More Information]
  • Smith, M., Gill, P., Wetzig, N., Sourjina, T., Gebski, V., Ung, O., Campbell, I., Kollias, J., Coskinas, X., Macphee, A., Simes, R., Stockler, M., et al (2008). Comparing patients' and clinicians' assessment of outcomes in a randomised trial of sentinel node biopsy for breast cancer (the RACS SNAC trial). Breast Cancer Research and Treatment, Online (117)((1)), 1 (99)-11 (109). [More Information]
  • Duric, V., Butow, P., Sharpe, L., Heritier, S., Boyle, F., Beith, J., Wilcken, N., Coates, A., Simes, R., Stockler, M. (2008). Comparing patients' and their partners' preferences for adjuvant chemotherapy in early breast cancer. Patient Education and Counseling, 72(2), 239-245. [More Information]
  • Stewart, R., North, F., Sharples, K., Simes, R., Tonkin, A., White, H. (2008). Differences in cardiovascular mortality between Australia and New Zealand according to socioeconomic status: findings from the Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study. New Zealand Medical Journal, 121(1269), 11-23.
  • Kearney, P., Blackwell, L., Collins, R., Keech, A., Simes, R., Peto, R., Armitage, J., Baigent, C. (2008). Efficacy of cholesterol-lowering therapy in 18 686 people with diabetes in 14 randomised trials of statins: a meta-analysis. The Lancet, 371, 117-125. [More Information]
  • Keech, A., Mitchell, P., Summanen, P., Davis, T., Simes, R. (2008). Fenofibrate and diabetic retinopathy - Authors' reply. The Lancet, 371(9614), 722-722.
  • Berger, J., Stebbins, A., Granger, C., Ohman, E., Armstrong, P., Van de Werf, F., White, H., Simes, R., Harrington, R., Califf, R., et al (2008). Initial Aspirin Dose and Outcome Among ST-Elevation Myocardial Infarction Patients Treated With Fibrinolytic Therapy. Circulation (Baltimore), 117(2), 192-199. [More Information]
  • Karapetis, C., Khambata-Ford, S., Jonker, D., O'Callaghan, C., Tu, D., Tebbutt, N., Simes, R., Chalchal, H., Shapiro, J., Robitaille, S., et al (2008). K-ras Mutations and Benefit from Cetuximab in Advanced Colorectal Cancer. New England Journal of Medicine, 359(17), 1757-1765. [More Information]
  • Glasziou, P., Irwig, L., Heritier, S., Simes, R., Tonkin, A. (2008). Monitoring cholesterol levels: Measurement error or true change? Annals of Internal Medicine, 148(9), 656-661. [More Information]
  • Cui, J., Forbes, A., Kirby, A., Marschner, C., Simes, R., West, M., Tonkin, A. (2008). Parametric conditional frailty models for recurrent cardiovascular events in the lipid study. Clinical Trials, 5(6), 565-574. [More Information]
  • Kearney, P., Keech, A., Simes, R., Collins, R. (2008). Statins and diabetes: authors' reply. The Lancet, 371(9626), 1752-1752.
  • Dwan, K., Altman, D., Arnaiz, J., Bloom, J., Chan, A., Cronin, E., Decullier, E., Easterbrook, P., Von Elm, E., Gamble, C., Ghersi, D., Simes, R., et al (2008). Systematic Review of the Empirical Evidence of Study Publication Bias and Outcome Reporting Bias. PloS One, 3(8), e3081-1-e3081-31. [More Information]
  • Lord, S., Lee, C., Simes, R. (2008). The Role of Predictive and Prognostic Markers in Cancer. Cancer Forum, 32(3), 139-142.
  • West, M., Nestel, P., Kirby, A., Schnabel, R., Sullivan, D., Simes, R., Pollicino, C., Lubos, E., Munzel, T., White, H., et al (2008). The value of N-terminal fragment of brain natriuretic peptide and tissue inhibitor of metalloproteinase-1 levels as predictors of cardiovascular outcome in the LIPID study. European Heart Journal, 29(7), 923-931. [More Information]
  • Lord, S., Irwig, L., Simes, R. (2007). A philosophical approach to diagnostic test evaluation - In Response. Annals of Internal Medicine, 146(10), 757-758.
  • Marschner, C., Simes, R., Keech, A. (2007). Biases in the Identification of Risk Factor Thresholds and J-Curves. American Journal of Epidemiology, 166(7), 824-831. [More Information]
  • Smith, M., Gill, P., Wetzig, N., Sourjina, T., Simes, R., Stockler, M. (2007). Bs06 patient-rated outcome measures were more sensitive than clinician-rated measures at distinguishing the effects of sentinel node biopsy and axillary clearance in the snac trial. ANZ Journal of Surgery, 77(Suppl. 1), A2-A2. [More Information]
  • Mark, D., Van de Werf, F., Simes, R., White, H., Wallentin, L., Califf, R., Armstrong, P. (2007). Cardiovascular disease on a global scale: defining the path forward for research and practice. European Heart Journal, 28(21), 2678-2684. [More Information]
  • Jonker, D., O’Callaghan, C., Karapetis, C., Zalcberg, J., Tu, D., Au, H., Berry, S., Krahn, M., Price, T., Simes, R., et al (2007). Cetuximab for the Treatment of Colorectal Cancer. New England Journal of Medicine, 357(20), 2040-2048. [More Information]
  • Grimison, P., Simes, R., Stockler, M. (2007). Development and validation of optimally weighted measures of global health-related quality of life (QoL) and utility based on a cancer-specific QoL instrument. Value in Health, 10(6), A226-A227.
  • Keech, A., Mitchell, P., Summanen, P., O'Day, J., Davis, T., Moffitt, M., Taskinen, M., Simes, R., Tse, D., Williamson, E., Merrifield, A., O'Connell, R., et al (2007). Effect of fenofibrate on the need for laser treatment for diabetic retinopathy (FIELD study): a randomised controlled trial. The Lancet, 370(9600), 1687-1697. [More Information]
  • Stockler, M., O'Connell, R., Nowak, A., Goldstein, D., Turner, J., Wilcken, N., Wyld, D., Abdi, E., Glasgow, A., Beale, P., Dhillon, H., Heritier, S., Carter, C., Hickie, I., Simes, R., et al (2007). Effect of sertraline on symptoms and survival in patients with advanced cancer, but without major depression: a placebo-controlled double-blind randomised trial. Lancet Oncology, 8(7), 603-612. [More Information]
  • Timmer, J., Ottervanger, J., de Boer, M., Boersma, E., Grines, C., Westerhout, C., Simes, R., Granger, C., Zijlstra, F., Primary Coronary Angioplasty vs Thrombolysis–2 Trialists, C. (2007). Primary percutaneous coronary intervention compared with fibrinolysis for myocardial infarction in diabetes mellitus: results from the Primary Coronary Angioplasty vs Thrombolysis-2 trial. Archives of Internal Medicine, 167(13), 1353-1359. [More Information]
  • Duric, V., Butow, P., Sharpe, L., Boyle, F., Beith, J., Wilcken, N., Heritier, S., Coates, A., Simes, R., Stockler, M. (2007). Psychosocial factors and patients' preferences for adjuvant chemotherapy in early breast cancer. Psycho-Oncology: journal of the psychological, social and behavioral dimensions of cancer, 16(1), 48-59. [More Information]
  • Gebski, V., Burmeister, B., Smithers, B., Foo, K., Zalcberg, J., Simes, R. (2007). Survival benefits from neoadjuvant chemoradiotherapy or chemotherapy in oesophageal carcinoma: a meta-analysis. Lancet Oncology, 8(3), 226-234. [More Information]
  • Edmond, J., French, J., Aylward, P., Wong, C., Stewart, R., Williams, B., de Pasquale, C., O'Connell, R., van den Berg, K., Van de Werf, F., Simes, R., et al (2007). Variations in the use of emergency PCI for the treatment of re-infarction following intravenous fibrinolytic therapy: impact on outcomes in HERO-2. European Heart Journal, 28(12), 1418-1424. [More Information]
  • Stockler, M., Sourjina, T., Harvey, V., Frances, P., Byrne, M., van Hazel, G., Fitzharris, B., Ackland, S., Finch, K., Lindsay, D., Gebski, V., Simes, R., Coates, A., et al (2006). A randomized trial of capecitabine given intermittently versus continuously versus classical CMF as first line chemotherapy for women with advanced breast cancer unsuited to more intensive treatment. Breast Cancer Research and Treatment, 100(Supplement 1), S278-S278.
  • Keech, A., Simes, R. (2006). Clinical trial design & management: The role of PPAR-ALPHA agonists in prevention of CVD. Atherosclerosis Supplements, 7(3), 174-174.
  • Keech, A., Simes, R., Barter, P., Best, J., Scott, R., Taskinen, M. (2006). Correction to the FIELD study report. The Lancet, 368(9545), 1415. [More Information]
  • Tonkin, A., Eckermann, S., White, H., Friedlander, D., Glasziou, P., Magnus, P., Kirby, A., Mulray, S., Denton, M., Sallaberger, M., Simes, R., et al (2006). Cost-effectiveness of cholesterol-lowering therapy with pravastatin in patients with previous acute coronary syndromes aged 65 to 74 years compared with younger patients: results from the LIPID study. American Heart Journal, 151(6), 1305-1312. [More Information]
  • Stockler, M., Tattersall, M., Boyer, M., Clarke, S., Beale, P., Simes, R. (2006). Disarming the guarded prognosis: predicting survival in newly referred patients with incurable cancer. British Journal of Cancer, 94(2), 208-212. [More Information]
  • Boersma, E., Westerhout, C., Simes, R., Weaver, W., Andersen, H., Armstrong, P., Granger, C., Grines, C., Zijlstra, F., Widimsky, P., et al (2006). Does time matter? A pooled analysis of randomized clinical trials comparing primary percutaneous coronary intervention and in-hospital fibrinolysis in acute myocardial infarction patients. European Heart Journal, 27(7), 779-788. [More Information]
  • Baigent, C., Keech, A., Kearney, P., Collins, R., Simes, R. (2006). Efficacy and safety of cholesterol-lowering treatment - Reply. The Lancet, 367(9509), 470-471.
  • Baigent, C., Keech, A., Kearney, P., Collins, R., Simes, R. (2006). Efficacy and safety of cholesterol-lowering treatment-authors' reply [letter]. The Lancet, 367(9509), 470-471.
  • Edmond, J., French, J., Stewart, R., Aylward, P., de Pasquale, C., Williams, B., O'Connell, R., Simes, R., White, H. (2006). Frequency of recurrent ST-elevation myocardial infarction after fibrinolytic therapy in a different territory as a manifestation of multiple unstable coronary arterial plaques. The American Journal of Cardiology, 97(7), 947-951. [More Information]
  • Alexander, K., Newby, L., Bhapkar, M., White, H., Hochman, J., Pfisterer, M., Moliterno, D., Peterson, E., Van de Werf, F., Simes, R., Keech, A., et al (2006). International variation in invasive care of the elderly with acute coronary syndromes. European Heart Journal, 27(13), 1558-1564. [More Information]
  • Tonelli, M., Isles, C., Craven, T., Furberg, C., Tonkin, A., Pfeffer, M., Shepherd, J., Cobbe, S., Sacks, F., Simes, R., et al (2006). Letter regarding article by Tonelli et al, "Effect of pravastatin on rate of kidney function loss in people with or at risk for coronary disease" - Response. Circulation Journal, 113, e59-e60. [More Information]
  • Galbraith, S., Marschner, I., Simes, R. (2006). Missing data methods for the assessment of surrogate outcomes and treatment mechanisms in clinical trial substudies. Statistics in Medicine, 25(3), 415-431. [More Information]
  • Stocker, R., Pollicino, C., Gay, C., Nestel, P., Colquhoun, D., Whiting, M., Tonkin, A., Sullivan, D., Simes, R. (2006). Neither plasma coenzyme Q(10) concentration, nor its decline during pravastatin therapy, is linked to recurrent cardiovascular disease events: A prospective case-control study from the LIPID study. Atherosclerosis, 187(1), 198-204. [More Information]
  • Orlandini, A., Diaz, R., Wojdyla, D., Pieper, K., Van de Werf, F., Granger, C., Harrington, R., Boersma, E., Califf, R., Armstrong, P., Simes, R., et al (2006). Outcomes of patients in clinical trials with ST-segment elevation myocardial infarction among countries with different gross national incomes. European Heart Journal, 27(5), 527-533. [More Information]
  • Van Glabbeke, M., Verweij, J., Casali, P., Simes, R., Le Cesne, A., Reichardt, P., Issels, R., Judson, I., van Oosterom, A., Blay, J. (2006). Predicting toxicities for patients with advanced gastrointestinal stromal tumours treated with imatinib: a study of the European Organisation for Research and Treatment of Cancer, the Italian Sarcoma Group, and the Australasian Gastro-Intestinal Trials Gr. European Journal of Cancer, 42(14), 2277-2285. [More Information]
  • Askie, L., Ghersi, D., Simes, R. (2006). Prospective registration of clinical trials (editorial). Australian Journal of Physiotherapy, 52(4), 237-239.
  • Askie, L., Ghersi, D., Simes, R. (2006). Prospective registration of clinical trials [Editorial]. Australian Journal of Physiotherapy, 52(4), 237-239. [More Information]
  • Gill, P., Gebski, V., Wetzig, N., Ung, O., Campbell, I., Collins, J., Sourjina, T., Coskinas, X., Stockler, M., Simes, R. (2006). Sentinel node (SN) based management causes less arm swelling and better quality of life than routine axillary clearance (AC): 1 year outcomes of the SNAC trial. Breast Cancer Research and Treatment, 100(Supplement 1), S14-S14.
  • Bushnell, C., Griffin, J., Newby, L., Goldstein, L., Mahaffey, K., Graffagnino, C., Harrington, R., White, H., Simes, R., Califf, R., et al (2006). Statin use and sex-specific stroke outcomes in patients with vascular disease. Stroke: a journal of cerebral circulation, 37(6), 1427-1431.
  • Gebski, V., Lagleva, M., Keech, A., Simes, R., Langlands, A. (2006). Survival Effects of Postmastectomy Adjuvant Radiation Therapy Using Biologically Equivalent Doses: A Clinical Perspective - [Response]. Journal of the National Cancer Institute, 98(17), 1021-1022.
  • Gebski, V., Lagleva, M., Keech, A., Simes, R., Langlands, A. (2006). Survival effects of postmastectomy adjuvant radiation therapy using biologically equivalent doses: a clinical perspective. Journal of the National Cancer Institute, 98(1), 26-38. [More Information]
  • Keech, A., Simes, R., Barter, P., Best, J., Scott, R., Taskinen, M. (2006). The FIELD study - Reply. The Lancet, 367(9517), 1142-1143.
  • Lord, S., Irwig, L., Simes, R. (2006). When is measuring sensitivity and specificity sufficient to evaluate a diagnostic test, and when do we need randomized trials? Annals of Internal Medicine, 144(11), 850-855. [More Information]
  • Ackland, S., Jones, M., Tu, D., Simes, R., Yuen, J., Sargeant, A., Dhillon, H., Goldberg, R., Abdi, E., Moore, M., et al (2005). A meta-analysis of two randomised trials of early chemotherapy in asymptomatic metastatic colorectal cancer. British Journal of Cancer, 93(11), 1236-1243. [More Information]
  • O'Connell, R., Edmond, J., French, J., Aylward, P., Simes, R., White, H. (2005). A simple prognostic score for the re-infarction risk following fibrinolytic therapy for myocardial infarction - data from HERO-2. European Heart Journal, 26(Suppl 1), 561-561.
  • Ghersi, D., Wilcken, N., Simes, R. (2005). A systematic review of taxane-containing regimens for metastatic breast cancer. British Journal of Cancer, 93(3), 293-301. [More Information]
  • West, M., Blankenberg, S., Simes, R., Pollicino, C., Kirby, A., Nestel, P., White, H., Tonkin, A. (2005). Brain natriuretic peptide: a predictor of cardiovascular outcome in the Long-term Intervention with Pravastatin in Ischaemic Disease (LIPID) study. European Heart Journal, 26(Suppl 1), 718-718.
  • Duric, V., Stockler, M., Butow, P., Sharpe, L., Heritier, S., Beith, J., Boyle, F., Wilcken, N., Coates, A., Simes, R. (2005). Comparing patients' and their partners' preferences for adjuvant chemotherapy (ACT) in early breast cancer (EBC). Journal of Clinical Oncology, 23(16S), 546S-546S.
  • Sinnaeve, P., Simes, R., Yusuf, S., Garg, J., Mehta, S., Eikelboom, J., Bittl, J., Serruys, P., Topol, E., Granger, C. (2005). Direct thrombin inhibitors in acute coronary syndromes: effect in patients undergoing early percutaneous coronary intervention. European Heart Journal, 26(22), 2396-403. [More Information]
  • Tonelli, M., Keech, A., Shepherd, J., Sacks, F., Tonkin, A., Packard, C., Pfeffer, M., Simes, R., Isles, C., Furberg, C., et al (2005). Effect of pravastatin in people with chronic kidney disease and diabetes mellitus. Hypertension, 46(4), 900-901.
  • Tonelli, M., Keech, A., Shepherd, J., Sacks, F., Tonkin, A., Packard, C., Pfeffer, M., Simes, R., Isles, C., Furberg, C., et al (2005). Effect of pravastatin in people with diabetes and chronic kidney disease. Journal of the American Society of Nephrology, 16(12), 3748-3754. [More Information]
  • Tonelli, M., Isles, C., Craven, T., Tonkin, A., Pfeffer, M., Shepherd, J., Sacks, F., Furberg, C., Cobbe, S., Simes, R., et al (2005). Effect of pravastatin on rate of kidney function loss in people with or at risk for coronary disease. Circulation, 112(2), 171-178. [More Information]
  • Keech, A., Simes, R., Barter, P., Best, J., Scott, R., Taskinen, M., Forder, P., Pillai, A., Davis, T., Glasziou, P., Sullivan, D., MacMahon, S., et al (2005). Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. The Lancet, 366(9500), 1849. [More Information]
  • Baigent, C., Keech, A., Kearney, P., Blackwell, L., Buck, G., Pollicino, C., Kirby, A., Sourjina, T., Peto, R., Collins, R., Simes, R. (2005). Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. The Lancet, 366(9493), 1267-1278. [More Information]
  • Scott, R., Best, J., Forder, P., Taskinen, M., Simes, R., Barter, P., Keech, A. (2005). Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study: baseline characteristics and short-term effects of fenofibrate (ISRCTN64783481). Cardiovascular Diabetology, 4(13), 1-9. [More Information]
  • Armstrong, P., Newby, L., Granger, C., Lee, K., Califf, R., Simes, R., Van de Werf, F., White, H. (2005). Letter regarding article by Armstrong et al, "Lessons learned from a clinical trial" - Response. Circulation (Baltimore), 111(23), e393-e393.
  • Labinaz, M., Mathias, J., Pieper, K., Granger, C., Lincoff, A., Moliterno, D., Van de Werf, F., Simes, R., White, H., Simoons, M., et al (2005). Outcomes of patients with acute coronary syndromes and prior percutaneous coronary intervention: a pooled analysis of three randomized clinical trials. European Heart Journal, 26(2), 128-136. [More Information]
  • Wong, C., French, J., Aylward, P., Stewart, R., Gao, W., Van de Werf, F., Armstrong, P., Simes, R., Raffel, O., Granger, C., et al (2005). Patients With Prolonged Ischemic Chest Pain and Presumed-New Left Bundle Branch Block Have Heterogeneous Outcomes Depending on the Presence of ST-Segment Changes. Journal of the American College of Cardiology, 46(1), 29-38. [More Information]
  • Duric, V., Stockler, M., Heritier, S., Boyle, F., Beith, J., Sullivan, A., Wilcken, N., Coates, A., Simes, R. (2005). Patients' preferences for adjuvant chemotherapy in early breast cancer: what makes AC and CMF worthwhile now? Annals of Oncology, 16(11), 1786-1794. [More Information]
  • Nestel, P., Baghurst, K., Colquhoun, D., Simes, R., Mehalski, K., White, H., Tonkin, A., Kirby, A., Pollicino, C. (2005). Relation of diet to cardiovascular disease risk factors in subjects with cardiovascular disease in Australia and New Zealand: analysis of the Long-Term Intervention with Pravastatin in Ischaemic Disease trial. American Journal of Clinical Nutrition, 81(6), 1322-1329. [More Information]
  • Carrick, S., Parker, S., Thornton, C., Ghersi, D., Simes, R., Wilcken, N. (2005). Single agent versus combination chemotherapy for metastatic breast cancer (Review). Cochrane Database of Systematic Reviews, 2005 (2), 1-22. [More Information]
  • Burmeister, B., Smithers, B., Gebski, V., Fitzgerald, L., Simes, R., Devitt, P., Ackland, S., Gotley, D., Joseph, D., Millar, J., Walpole, E., et al (2005). Surgery alone versus chemoradiotherapy followed by surgery for resectable cancer of the oesophagus: a randomised controlled phase III trial. Lancet Oncology, 6(9), 659-668. [More Information]
  • Ghersi, D., Wilcken, N., Simes, R., Donoghue, E. (2005). Taxane containing regimens for metastatic breast cancer (Review). Cochrane Database of Systematic Reviews, 2005 (2), 1-119. [More Information]
  • Nestel, P., Blankenberg, S., Simes, R., Kirby, A., Tonkin, A. (2005). Tissue inhibitor of metalloproteinase (TIMP-1) is a predictor of recurrent cardiovascular events in the LIPID study. European Heart Journal, 26(Suppl 1), 257-257.
  • Stewart, R., White, H., Kirby, A., Heritier, S., Simes, R., Nestel, P., West, M., Colquhoun, D., Tonkin, A. (2005). White Blood Cell Count Predicts Reduction in Coronary Heart Disease Mortality With Pravastatin. Circulation, 111(14), 1756-1762. [More Information]
  • Cox, K., O'Connell, R., Stockler, M., Boyer, M., Beale, P., Simes, R. (2004). A randomized crossover trial of giving high-dose cisplatin with or without an overnight stay in hospital: Patients' preferences, quality of life, safety and resource use. Journal of Clinical Oncology, 22(14S), 547S-547S.
  • Lord, S., Ghersi, D., Gattellari, M., Wilcken, N., Thornton, C., Simes, J. (2004). Antitumour Antibiotic Containing Regimens For Metastatic Breast Cancer. Cochrane Database of Systematic Reviews, 4(CD003367), 1-123.
  • Boersma, E., Simes, R., Grines, C., Westerhout, C. (2004). Does time matter? Individual patient data-based meta-analysis of primary PCI versus fibrinolysis in acute myocardial infarction randomized trials. Circulation, 110(Suppl III), III 539-III 539.
  • Colquhoun, D., Keech, A., Hunt, D., Marschner, C., Simes, R., Glasziou, P., White, H., Barter, P., Tonkin, A. (2004). Effects Of Pravastatin On Coronary Events In 2073 Patients With Low Levels Of Both Low-Density Lipoprotein Cholesterol And High-Density Lipoprotein Cholesterol: Results From The Lipid Study. European Heart Journal, 25(9), 771-777. [More Information]
  • Kassem-Moussa, H., Mahaffey, K., Graffagnino, C., Tassisa, G., Sila, C., Simes, R., White, H., Califf, R., Bhapkar, M., Newby, L. (2004). Incidence and characteristics of stroke during 90-day follow-up in patients stabilized after an acute coronary syndrome. American Heart Journal, 148(3), 439-446. [More Information]
  • Armstrong, P., Newby, L., Granger, C., Lee, K., Simes, R., Van de Werf, F., White, H., Califf, R. (2004). Lessons learned from a clinical trial. Circulation (Baltimore), 110(23), 3610-3614.
  • Carrick, S., Ghersi, D., Wilcken, N., Simes, R. (2004). Platinum Containing Regimens For Metastatic Breast Cancer. Cochrane Database of Systematic Reviews, 2(CD003374), 1-74.
  • Duric, V., Stockler, M., Butow, P., Sharpe, L., Beith, J., Sullivan, A., Boyle, F., Dhillon, H., Coates, A., Simes, R. (2004). Predictors of the benefits women consider necessary to make adjuvant chemotherapy (ACT) worthwhile for early breast cancer (EBC). Journal of Clinical Oncology, 22(14S), 73S-73S.
  • Kandzari, D., Granger, C., Simoons, M., White, H., Simes, R., Mahaffey, K., Gore, J., Weaver, W., Longstreth, W., Stebbins, A., et al (2004). Risk Factors For Intracranial Hemorrhage And Nonhemorrhagic Stroke After Fibrinolytic Therapy (From The Gusto-I Trial). The American Journal of Cardiology, 93(4), 458-461. [More Information]
  • Keech, A., Best, J., Scott, R., Barter, P., Simes, R., Forder, P., Taskinen, M., FIELD study investigators, F. (2004). Significant lipid changes in a large-scale trial of fenofibrate to prevent cardiovascular disease in type 2 diabetes. Journal of the American College of Cardiology, 43(5), A462-A462.
  • Simes, R., Gebski, V., Keech, A. (2004). Subgroup analysis: application to individual patient decisions. Medical Journal of Australia, 180(9), 467-469. [More Information]
  • Barter, P., Best, J., Colman, P., D'Emden, M., Davis, T., Drury, P., Ehnholm, C., Glasziou, P., Hunt, D., Keech, A., Forder, P., Simes, R., et al (2004). The need for a large-scale trial of fibrate therapy in diabetes: the rationale and design of the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study. Cardiovascular Diabetology, 3(December), 9 - 1-9 - 11.
  • Glare, P., Virik, K., Jones, M., Hudson, M., Eychmuller, S., Simes, R., Christakis, N. (2003). A systematic review of physicians' survival predictions in terminally ill cancer patients. BMJ: British Medical Journal, 327(195), 195-198.
  • Magliano, D., Liew, D., Pater, H., Kirby, A., Hunt, D., Simes, R., Sundararajan, V., Tonkin, A. (2003). Accuracy of the Australian National Death Index: comparison with adjudicated fatal outcomes among Australian participants in the long-term intervention with Pravastatin in Ischaemic Disease (LIPID) Study. Australian and New Zealand Journal of Public Health, 27(6), 649-653. [More Information]
  • Pike, R., Keech, A., Simes, R. (2003). Clinical trials research in the new millennium: the International Clinical Trials Symposium, Sydney, 21-23 October 2002. Medical Journal of Australia, 178(7), 316-317.
  • Stewart, R., North, F., West, T., Sharples, K., Simes, R., Colquhoun, D., White, H., Tonkin, A. (2003). Depression and cardiovascular morbidity and mortality: cause or consequence? European Heart Journal, 24, 2027-2037. [More Information]
  • Hague, W., Forder, P., Simes, R., Hunt, D., Tonkin, A. (2003). Effect of pravastatin on cardiovascular events and mortality in 1516 women with coronary heart disease: Results from the Long-Term Intervention with Pravastatin in Ischemic Disease (LIPID) study. American Heart Journal, 145(4), 643-651.
  • Kramer, J., Newby, L., Chang, W., Simes, R., Van de Werf, F., Granger, C., Lee, K., White, H., Piegas, L., Topol, E., et al (2003). International variation in the use of evidence-based medicines for acute coronary syndromes. European Heart Journal, 24(23), 2133-2141. [More Information]
  • Patel, A., Jones, M., Simes, R., Topol, E., Califf, R., Van, D., Betriu,, A., Ardissino,, D., Armstrong, P., Aylward, P., et al (2003). Primary coronary angioplasty compared with intravenous thrombolytic therapy for acute myocardial infarction: six-month follow up and analysis of individual patient data from randomized trials. American Heart Journal, 145(1), 48-57.
  • Keech, A., Colquhoun, D., Best, J., Kirby, A., Simes, R., Hunt, D., Hague, W., Beller, E., Arulchelvam, M., Baker, J., et al (2003). Secondary prevention of cardio vascular events with long-term Pravastatin in patients with diabetes or impared fasting glucose: results from the LIPID trial. Diabetes Care, 26(10), 2713-2721.
  • Ghersi, D., Wilcken, N., Simes, R., Donoghue, E. (2003). Taxane containing regimes for metastatic breast cancer. Cochrane Database of Systematic Reviews, 168(37), 3117-3120. [More Information]
  • Eckermann, S., Martin, A., Stockler, M., Simes, R. (2003). The benefits and costs of tamoxifen for breast cancer prevention. Australian and New Zealand Journal of Public Health, 27(1), 34-40.
  • Coates, A., Thompson, J., McMullen, A., Simes, R., McCarthy, W., Hersey, P., Sillar, R., Mcleod, R., Gill, P., Coventry, B., Dhillon, H. (2002). Adjuvant Immunotherapy of Patients with High-Risk Melanoma Using Vaccinia Viral Lysates of Melanoma: Results of a Randomized Trial. Journal of Clinical Oncology, 20(20), 4181-4189.
  • Glasziou, P., Eckermann, S., Mulray, S., Simes, R., Martin, A., Kirby, A., Hall, J., White, H., Caleo, S., Tonkin, A. (2002). Cholesterol-lowering therapy with pravastatin in patients with average cholesterol levels and establisheed ischaemic heart disease: is it cost effective? Medical Journal of Australia, 177(8), 428-434.
  • Zijlstra, F., Patel, A., Jones, W., Grines, C., Ellis, S., Garcia, E., Grinfeld, L., Gibbons, R., Ribeiro, E., Ribichini, F., Simes, R., et al (2002). Clinical characteristics and outcome of patients with early(<2h), intermediate (2-4h) and late (>4h) presentation treated by primary coronary angioplasty or thrombolytic therapy for acute myocardial infarction. European Heart Journal, 23(7), 550-557.
  • Simes, R., Furberg, C., Braunwald, E., Davis, B., Ford, I., Tonkin, A., Shepherd, J., Keech, A. (2002). Effects of pravastatin on mortality in patients with and without coronary heart disease across a broad range of cholesterol levels. European Heart Journal, 23(3), 207-215.
  • Cuzick, J., Forbes, J., Edwards, R., Baum, M., Cawthorn, S., Coates, A., Hamed, H., Howell, A., Powels, T., Dhillon, H., Gebski, V., Simes, R. (2002). First results from the International Breast Cancer Intervention Study (IBIS-1): a randomised prevention trial. The Lancet, 360(9336), 817-824.
  • Cuzjik, J., Dhillon, H., Gebski, V., Simes, R. (2002). First results from the International Breast Cancer Intervention Study (IBIS-I): a randomised prevention trial. The Lancet, 360(9336), 817-824.
  • Simes, R., Kirby, A., Keech, A., Hague, W., MacMahon, S., Hunt, D., Tonkin, A., Alyward, P., Colquhoun, D., Glasziou, P., et al (2002). Long-term effectiveness and safety of pravastatin in 9014 patients with coronary heart disease and average cholesterol concentrations: the LIPID trial follow up. The Lancet, 359, 1379-1387.
  • Boersma, E., Harrington, R., Moliterno, D., White, H., Theroux, P., Van de Werf, F., Torbal, A., Armstrong, P., Wallentin, L., Wilcox, R., Simes, R., et al (2002). Platelet glycoprotein IIb/IIIa inhibitors in acute coronary syndromes: a meta-analysis of all major randomised clinical trials. The Lancet, 359(9302), 189-198.
  • Simes, R., Keech, A., et, A. (2002). Randomized, placebo-controlled trial of titrated intravenous lamifiban for acute coronary syndromes. Circulation, 105(3), 316-321.
  • Simes, R., Marschner, C., Hunt, D., Sullivan, D., Colquhoun, D., Hague, W., Stewart, R., Keech, A., Thompson, P., White, H., et al (2002). Relationship between lipid levels and clinical outcomes in the long-term intervention with pravastatin in ischemic disease (LIPID) trial: to what extent is the reduction in coronary events with pravastatin explained by on-study lipid levels? Circulation, 105(10), 1162-1169.
  • West, M., White, H., Simes, R., Kirby, A., Watson, J., Anderson, N., Hankey, G., Simes, S., Hunt, D., Tonkin, A. (2002). Risk factors for non-haemorraghic stroke in patients with coronary heart disease and the effect of lipid-modifying therapy with pravastatin. Journal of Hypertension, 20(12), 2513-2517.
  • Al-Khatib, S., Huang, Y., Califf, R., Lee, K., Simoons, M., Van de Werf, F., White, H., Simes, R., Granger, C., Armstrong, P., et al (2002). Sustained ventricular arrythmias among patients with acute coronary syndromes with no ST-segment elevation: incidence, predictors and outcomes. Circulation, 106(3), 309-312.
  • Armstrong, P., Newby, L., Califf, R., White, H., Harrington, R., Van de Werf, F., Granger, C., Simes, R., Hasselblad, V. (2002). The failure of orally administered glycoprotein IIb/IIIa inhibitors to prevent recurrent cardiac events. The American Journal of Medicine, 112(8), 647-658.
  • Ghersi, D., Simes, R., Stockler, M., Tattersall, M., Wilcken, N., Henderson, I., Basser, R., Brunswick, C., Fossati, C., Liberati, A., et al (2001). Addition of drug/s to a chemotherapy regimen for metastatic breast cancer [protocol]. Cochrane Database of Systematic Reviews, Issue 4, 1-4.
  • Ghersi, D., Simes, R., Stockler, M., Tattersall, M., Wilcken, N., Basser, R., Henderson, I., Brunswick, C., Fossati, R., Liberati, A., et al (2001). Antitumor antibiotic containing regimins for metastatic breast cancer [protocol]. Cochrane Database of Systematic Reviews, Issue 4, 1-4.
  • Hunt, D., Young, P., Simes, R., Hague, W., Mann, S., Owensby, D., Lane, G., Tonkin, A. (2001). Benefits of pravastatin on cardiovascular events and mortality in older patients with coronary heart disease are equal to or exceed those seen in younger patients. Annals of Internal Medicine, (134), 931-940.
  • Simes, R., Hague, W., Young, P., Hunt, D., Mann, S., Owensby, D., Lande,, G., Tonkin, A. (2001). Benefits of pravastatin on cardiovascular events and mortalty in older patients with coronary heart disease are equpal to or exceed those seen isn younder patients: results from LIPID Trial. Annals of Internal Medicine, 134 (10), 931-940.
  • Lumley, T., Simes, R., Gebski, V., Hudson, H. (2001). Combining components of quality of life to increase precision and evaluate trade-offs. Statistics in Medicine, 20(21), 3231-3249.
  • Lumley, T., Simes, R., Gebski, V., Hudson, M. (2001). Combining components of quality of life to increase precision and evaluate trade-offs. Statistics in Medicine, 20, 3231-3249.
  • Toner, G., Stockler, M., Boyer, M., Jones, M., Thomson, D., Harvey, V., Olver, I., Dhillon, H., McMullen, A., Gebski, V., Levi, J., Simes, R. (2001). Comparison of two standard chemotherapy regimens for good-prognosis germ-cell tumours: a randomised trial. The Lancet, 357(9528), 739-745.
  • Jeffery, H., Simes, R., Lawrence, G., Tudehope, D., Baumann,, K., Gill, A., Cole, M., Drew, J., McPhee,, A., Ratcliffe, J., et al (2001). Enteral human IgG for prevention of necrotising enterocolitis: a placebo-controlled, randomised trial. The Lancet, 357, 2090-2094.
  • Gebski, V., Veness, M., Simes, R., Shakespeare, T. (2001). Improving interpretation of clinical studies by use of confidence intervals, clinical significnce cureves, and risk analysis. The Lancet, 357, 1349-1353.
  • Shakespeare, T., Gebski, V., Veness, M., Simes, R. (2001). Improving interpretation of clinical studies by use of confidence levels, clinical significance curves, and risk-benefit contours. The Lancet, 357(9265), 1349-1353.
  • Ghersi, D., Simes, R., Stockler, M., Tattersall, M., Wilcken, N., Henderson, I., Basser, R., Brunswick, C., Fossati, R., Liberati, A., et al (2001). Larger vs smaller dose of the same drug/s regimen for metastatic breast cancer [protocol]. Cochrane Database of Systematic Reviews, Issue 4, 1-4.
  • Marschner, C., Simes, R., Colquhoun, D., Glasziou, P., Harris, P., Singh, B., Friedlander, D., White, H., Thompson, P., Tonkin, A. (2001). Long-term risk stratification for survivors of acute coronary syndromes. Journal of the American College of Cardiology, 38(1), 56-63.
  • Simes, R., Coates, A. (2001). Patient preferences for adjuvant chemotherapy of early breast cancer: How much benefit is needed? Journal of the National Cancer Institute, 30, 146-152.
  • Ghersi, D., Simes, R., Stockler, M., Tattersall, M., Wilcken, N., Henderson, I., Basser, R., Brunswick, C., Fossati, R., Liberati, A., et al (2001). Platinum containing reimens for metastatic breast cancer [protocol]. Cochrane Database of Systematic Reviews, Issue 4, 1-4.
  • Ghersi, D., Simes, R., Stockler, M., Tattersall, M., Wilcken, N., Henderson, I., Basser, R., Brunswick, C., Fossati, R., Liberati, A., et al (2001). Single agent vs combination chemotherapy for metastatic breast cancer [protocol]. Cochrane Database of Systematic Reviews, Issue 4, 1-4.
  • Ghersi, D., Simes, R., Stockler, M., Tattersall, M., Wilcken, N., Henderson, I., Basser, R., Brunswick, C., Fossati, C., Liberati, A., et al (2001). Taxane containing regimens for metastatsic breast cancer [protocol]. Cochrane Database of Systematic Reviews, Issue 4, 1-4.
  • Ghersi, D., Simes, R., Stockler, M., Tattersall, M., Wilcken, N., Henderson, I., Basser, R., Brunswick, C., Fossati, R., Liberati, A., et al (2001). Two drug combinations vs combinations of 3 or more cytotoxic drugs for meastatic brest cancer [protocol]. Cochrane Database of Systematic Reviews, Issue 4, 1-4.
  • Stockler, M., Wilcken, N., Ghersi, D., Simes, R. (2000). Systematic reviews of chemotherapy and endocrine therapy in metastatic breast cancer. Cancer Treatment Reviews, 26(3), 151-168.

Conferences

  • Sullivan, D., Forder, P., Simes, R., Whiting, M., Keech, A. (2006). Individual and combined effects of fenofibrate and sulphonylureas on HDL cholesterol and outcomes. XIV International Symposium on Atherosclerosis, Ireland: Elsevier Ireland Ltd.
  • Colquhoun, D., Soderberg, S., Kirby, A., Keech, A., Simes, R., Hague, W., Hamilton-Craig, I., Tonkin, A. (2006). Obesity and adipokines as risk factors for major coronary heart disease events in patients with CHD: Results from the lipid trial. XIV International Symposium on Atherosclerosis, Ireland: Elsevier Ireland Ltd.
  • Gebski, V., Lagleva, M., Simes, R., Keech, A., Langlands, A. (2005). Adjuvant Radiotherapy in Early Breast Cancer: The Clinical Utility of Published Meta-Analysis. RANZCR, 55th Annual Scientific Meeting.
  • Gebski, V., Heritier, S., Pillai, A., Luke, V., Simes, R., Keech, A. (2005). Computer modelling of adaptive randomisation schemes in large scale randomised controlled trials. 20th International Workshop on Statistical Modelling, Sydney, Australia: University of Western Sydney.
  • Gebski, V., Simes, R. (2002). Survival plots for interpreting trial results. International Clinical Trials Symposium.

2014

  • Simes, R., Becattini, C., Agnelli, G., Eikelboom, J., Kirby, A., Mister, R., Prandoni, P., Brighton, T. (2014). Aspirin for the Prevention of Recurrent Venous Thromboembolism: The INSPIRE Collaboration. Circulation (Baltimore), 130(13), 1062-1071. [More Information]
  • White, H., Tonkin, A., Simes, R., Stewart, R., Mann, K., Thompson, P., Colquhoun, D., West, M., Nestel, P., Sullivan, D., Keech, A., et al (2014). Association of Contemporary Sensitive Troponin I Levels at Baseline and Change at 1 Year With Long - Term Coronary Events Following Myocardial Infarction or Unstable Angina. Journal of the American College of Cardiology, 63(4), 345-354. [More Information]
  • Jonker, D., Karapetis, C., Harbison, C., O’Callaghan, C., Tu, D., Simes, R., Malone, D., Langer, C., Tebbutt, N., Price, T., et al (2014). Epiregulin gene expression as a biomarker of benefit from cetuximab in the treatment of advanced colorectal cancer. British Journal of Cancer, 110(3), 648-655. [More Information]
  • Funke-Kaiser, A., Mann, K., Colquhoun, D., Zeller, T., Hunt, D., Simes, R., Sullivan, D., Sydow, K., West, M., White, H., et al (2014). Midregional proadrenomedullin and its change predicts recurrent major coronary events and heart failure in stable coronary heart disease patients: the LIPID study. International Journal of Cardiology, 172(2), 411-418. [More Information]
  • Chen, J., Hovey, E., Rosenthal, M., Ratcliffe, A., Simes, R. (2014). Neuro-oncology practices in Australia: A Cooperative Group for Neuro-Oncology patterns of care study. Asia-Pacific Journal of Clinical Oncology, 10(2), 162-167. [More Information]
  • Karapetis, C., Jonker, D., Daneshmand, M., Hanson, J., OCallghan, C., Marginean, C., Zalcberg, J., Simes, R., Moore, M., Tebbutt, N., et al (2014). PIK3CA, BRAF, and PTEN Status and Benefit from Cetuximab in the Treatment of Advanced Colorectal Cancer--Results from NCIC CTG/AGITG CO.17. Clinical Cancer Research, 20(3), 744-753. [More Information]
  • White, H., Tonkin, A., Simes, R., Stewart, R., Mann, K. (2014). Reply to Letter to the Editor: Troponin I to target treatments which reduce cardiovascular risk - while waiting for Godot. Journal of the American College of Cardiology, 636(25), 2876-2886.
  • Hudson, H., Lo, S., Simes, R., Tonkin, A., Heritier, S. (2014). Semiparametric methods for multistate survival models in randomised trials. Statistics in Medicine, 33, 1621-1645. [More Information]
  • Carter, H., Zannino, D., Simes, R., Schofield, D., Howard, K., Zalcberg, J., Price, T., Tebbutt, N. (2014). The cost effectiveness of bevacizumab when added to capecitabine, with or without mitomycin-C, in first line treatment of metastatic colorectal cancer: Results from the Australasian phase III MAX study. European Journal of Cancer, 50(3), 535-543. [More Information]
  • Glasziou, P., Irwig, L., Kirby, A., Tonkin, A., Simes, R. (2014). Which lipid measurement should we monitor? An analysis of the LIPID study. BMJ Open, 4(2), e003512. [More Information]

2013

  • Simes, R., Winship, I., McNeil, J. (2013). A funding model for public-good clinical trials. Medical Journal of Australia, 199(2), 90-91. [More Information]
  • Lee, C., Simes, R., Brown, C., Gebski, V., Pfisterer, J., Swart, A., Berton-Rigaud, D., Plante, M., Skeie-Jensen, T., Vergote, I., Lord, S., et al (2013). A prognostic nomogram to predict overall survival in patients with platinum-sensitive recurrent ovarian cancer. Annals of Oncology, 24(4), 937-943. [More Information]
  • Simes, R., Eikelboom, J., Brighton, T. (2013). Aspirin for preventing venous thromboembolism. The New England Journal of Medicine, 368(8), 773. [More Information]
  • Vickers, M., Karapetis, C., Tu, D., O'Callaghan, C., Price, T., Tebbutt, N., van Hazel, G., Shapiro, J., Pavlakis, N., Gibbs, P., Simes, R., et al (2013). Association of hypomagnesemia with inferior survival in a phase III, randomized study of cetuximab plus best supportive care versus best supportive care alone: NCIC CTG/AGITG CO.17. Annals of Oncology, 24(4), 953-960. [More Information]
  • White, H., Simes, R., Stewart, R., Blankenberg, S., Barnes, E., Marschner, C., Thompson, P., West, M., Zeller, T., Colquhoun, D., Keech, A., Sullivan, D., et al (2013). Changes in lipoprotein-associated phospholipase A2 activity predict coronary events and partly account for the treatment effect of pravastatin: results from the Long-Term Intervention with Pravastatin in Ischemic Disease study. Journal of the American Heart Association, 2(5), 1-12. [More Information]
  • Stenson, B., Tarnow-Mordi, W., Darlow, B., Simes, R., Juszczak, E., Askie, L., Battin, M., Bowler, U., Broadbent, R., Cairns, P., Donoghoe, M., Ghadge, A., Hague, W., Kirby, A., et al (2013). Oxygen Saturation and Outcomes in Preterm Infants. The New England Journal of Medicine, 368(22), 2094-2104. [More Information]
  • Siu, L., Shapiro, J., Jonker, D., Karapetis, C., Zalcberg, J., Simes, R., Couture, F., Moore, M., Price, T., Siddiqui, J., et al (2013). Phase III Randomized, Placebo-Controlled Study of Cetuximab Plus Brivanib Alaninate Versus Cetuximab Plus Placebo in PatientsWith Metastatic, Chemotherapy-Refractory, Wild-TypeK-RASColorectal Carcinoma: The NCIC Clinical Trials Group and AGITG CO.20 Trial. Journal of Clinical Oncology, 31(19), 2477-2484. [More Information]
  • Nestel, P., Barnes, E., Tonkin, A., Simes, R., Fournier, M., White, H., Colquhoun, D., Blankenberg, S., Sullivan, D. (2013). Plasma Lipoprotein(a) Concentration Predicts Future Coronary and Cardiovascular Events in Patients With Stable Coronary Heart Disease. Arteriosclerosis, Thrombosis, and Vascular Biology, 33(12), 2902-2908. [More Information]
  • Price, T., Hardingham, J., Lee, C., Townsend, A., Wrin, J., Wilson, K., Weickhardt, A., Simes, R., Murone, C., Tebbutt, N. (2013). Prognostic impact and the relevance of PTEN copy number alterations in patients with advanced colorectal cancer (CRC) receiving bevacizumab. Cancer Medicine, 2(3), 277-285. [More Information]
  • Martin, A., Simes, R. (2013). Quality-adjusted survival as an end point in breast cancer trials. Clinical Investigation, 3(6), 545-555. [More Information]
  • Anderson, C., Heeley, E., Huang, Y., Wang, J., Stapf, C., Delcourt, C., Lindley, R., Robinson, T., Lavados, P., Neal, B., Hata, J., Arima, H., Heritier, S., Li, Q., Woodward, M., Simes, R., Chalmers, J., et al (2013). Rapid Blood-Pressure Lowering in Patients with Acute Intracerebral Hemorrhage. The New England Journal of Medicine, 368(25), 2355-2365. [More Information]
  • Tarnow-Mordi, W., Simes, R., Cruz, M. (2013). Strategies to accelerate recruitment to NHMRC multi-centre clinical trials. Journal of Paediatrics and Child Health, 49(1), e103-e105. [More Information]
  • Simes, R., Webb, S. (2013). Sustaining Australian research through clinical trials and investigator networks. Medical Journal of Australia, 198(3), 127-128. [More Information]
  • Lee, C., Gebski, V., Coates, A., Veillard, A., Harvey, V., Tattersall, M., Byrne, M., Brigham, B., Forbes, J., Simes, R. (2013). Trade-offs in quality of life and survival with chemotherapy for advanced breast cancer: mature results of a randomized trial comparing single-agent mitoxantrone with combination cyclophosphamide, methotrexate, 5-fluorouracil and prednisone. SpringerPlus, 2(391), 1-10. [More Information]

2012

  • Boekholdt, S., Arsenault, B., Mora, S., Pedersen, T., LaRosa, J., Nestel, P., Simes, R., Durrington, P., Hitman, G., Welch, K., et al (2012). Association of LDL cholesterol, non-HDL cholesterol, and apolipoprotein B levels with risk of cardiovascular events among patients treated with statins: a meta-analysis. JAMA: The Journal of the American Medical Association, 307(12), 1302-1309. [More Information]
  • Ting, R., Keech, A., Drury, P., Donoghoe, M., Hedley, J., Jenkins, A., Davis, T., Lehto, S., Celermajer, D., Simes, R., Rajamani, K., et al (2012). Benefits and Safety of Long-Term Fenofibrate Therapy in People With Type 2 Diabetes and Renal Impairment - The FIELD Study. Diabetes Care, 35(2), 218-225. [More Information]
  • Price, T., Zannino, D., Wilson, C., Simes, R., Cassidy, J., Van Hazel, G., Robinson, B., Broad, A., Ganju, V., Ackland, S., Tebbutt, N. (2012). Bevacizumab is equally effective and no more toxic in elderly patients with advanced colorectal cancer: a subgroup analysis from the AGITG MAX trial: an international randomised controlled trial of Capecitabine, Bevacizumab and Mitomycin C. Annals of Oncology, 23(6), 1531-1536. [More Information]
  • Verry, H., Lord, S., Martin, A., Gill, G., Lee, C., Howard, K., Wetzig, N., Simes, R. (2012). Effectiveness and cost-effectiveness of sentinel lymph node biopsy compared with axillary node dissection in patients with early-stage breast cancer: a decision model analysis. British Journal of Cancer, 106(6), 1045-1052. [More Information]
  • Tonkin, A., Hunt, D., Voysey, M., Kesaniemi, Y., Hamer, A., Waites, J., Mahar, L., Mann, S., Glasziou, P., Forder, P., Simes, R., Keech, A. (2012). Effects of fenofibrate on cardiovascular events in patients with diabetes, with and without prior cardiovascular disease: The Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study. American Heart Journal, 163(3), 508-514. [More Information]
  • Dear, R., Barratt, A., Evans, A., Simes, R., Newsom, J., Kent, D., Crossing, S., Holliday, C., Segelov, E., Hruby, G., Tattersall, M. (2012). Identifying and prioritising gaps in colorectal cancer trials research in Australia. Medical Journal of Australia, 197(9), 507-511. [More Information]
  • Lee, C., Marschner, C., Simes, R., Voysey, M., Egleston, B., Hudes, G., de Souza, P. (2012). Increase in Cholesterol PredictsSsurvival Advantage in Renal Cell Carcinoma Patients Treated with Temsirolimus. Clinical Cancer Research, 18(11), 3188-3196. [More Information]
  • Emberson, J., Kearney, P., Blackwell, L., Newman, C., Reith, C., Bhala, N., Holland, L., Peto, R., Keech, A., Collins, R., Simes, R., et al (2012). Lack of effect of lowering LDL cholesterol on cancer: meta-analysis of individual data from 175 000 people in 27 randomised trials of statin therapy. PloS One, 7(1), 1-10. [More Information]
  • Staub, L., Dyer, S., Lord, S., Simes, R. (2012). Linking the evidence: intermediate outcomes in medical test assessments. International Journal of Technology Assessment in Health Care, 28(1), 52-58. [More Information]
  • Brighton, T., Eikelboom, J., Mann, K., Mister, R., Gallus, A., Ockelford, P., Gibbs, H., Hague, W., Xavier, D., Diaz, R., Kirby, A., Simes, R. (2012). Low-Dose Aspirin for Preventing Recurrent Venous Thromboembolism. The New England Journal of Medicine, 367(2), 1979-1987. [More Information]
  • Mihaylova, B., Emberson, J., Blackwell, L., Keech, A., Simes, R., Barnes, E., Voysey, M., Gray, A., Collins, R., Baigent, C., et al (2012). The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials. The Lancet, 380(9841), 581-590. [More Information]
  • Keech, A., Simes, R., Fulcher, J. (2012). The role of statin therapy in patients with lower vascular risk. Medical Journal of Australia, 197(3), 130-131. [More Information]
  • Staub, L., Lord, S., Simes, R., Dyer, S., Houssami, N., Chen, R., Irwig, L. (2012). Using patient management as a surrogate for patient health outcomes in diagnostic test evaluation. BMC Medical Research Methodology, 12, 1-12. [More Information]

2011

  • Lee, C., Hudson, M., Stockler, M., Coates, A., Ackland, S., Gebski, V., Lord, S., Friedlander, M., Boyle, F., Simes, R. (2011). A nomogram to predict survival time in women starting first-line chemotherapy for advanced breast cancer. Breast Cancer Research and Treatment, 129(2), 467-476. [More Information]
  • Sullivan, D., Forder, P., Simes, R., Whiting, M., Kritharides, L., Merrifield, A., Donoghoe, M., Colman, P., Neil, G., Haapamäki, H., Keech, A. (2011). Associations between the use of metformin, sulphonylureas, or diet alone and cardiovascular outcomes in 6005 patients with type 2 diabetes in the FIELD study. Diabetes Research and Clinical Practice, 94(2), 284-290. [More Information]
  • Stockler, M., Harvey, V., Francis, P., Byrne, M., Ackland, S., Fitzharris, B., Van Hazel, G., Wilcken, N., Grimison, P., Nowak, A., Zannino, D., Gebski, V., Coates, A., et al (2011). Capecitabine Versus Classical Cyclophosphamide, Methotrexate, and Fluorouracil As First-Line Chemotherapy for Advanced Breast Cancer. Journal of Clinical Oncology, 29(34), 4498-4504. [More Information]
  • Lee, C., Gurney, H., Brown, C., Sorio, R., Donadello, N., Tulunay, G., Meier, W., Bacon, M., Maenpaa, J., Petru, E., Gebski, V., Lord, S., Simes, R., et al (2011). Carboplatin–paclitaxel-induced leukopenia and neuropathy predict progression-free survival in recurrent ovarian cancer. British Journal of Cancer, 105(3), 360-365. [More Information]
  • Lee, C., Friedlander, M., Brown, C., Gebski, V., Georgoulopoulos, A., Vergote, I., Pignata, S., Donadello, N., Schmalfeldt, B., Delva, R., Lord, S., Simes, R., et al (2011). Early Decline in Cancer Antigen 125 as a Surrogate for Progression-Free Survival in Recurrent Ovarian Cancer. Journal of the National Cancer Institute, 103(17), 1338-1342. [More Information]
  • Davis, T., Ting, R., Best, J., Donoghoe, M., Drury, P., Sullivan, D., Jenkins, A., O'Connell, R., Whiting, M., Glasziou, P., Simes, R., Gebski, V., Keech, A., et al (2011). Effects of fenofibrate on renal function in patients with type 2 diabetes mellitus: the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) Study. Diabetologia, 54(2), 280-290. [More Information]
  • Goel, S., Simes, R., Beith, J. (2011). Exploratory analysis of cardiac biomarkers in women with normal cardiac function receiving trastuzumab for breast cancer. Asia-Pacific Journal of Clinical Oncology, 7(3), 276-280. [More Information]
  • de Boer, S., Barnes, E., Westerhout, C., Simes, J., Granger, C., Kastrati, A., Widimsky, P., de Boer, M., Zijlstra, F., Boersma, E. (2011). High-risk patients with ST-elevation myocardial infarction derive greatest absolute benefit from primary percutaneous coronary intervention: Results from the Primary Coronary Angioplasty Trialist versus Thrombolysis (PCAT)-2 Collaboration. American Heart Journal, 161(3), 500-507.e1. [More Information]
  • Dear, R., Barratt, A., McGeechan, K., Askie, L., Simes, R., Tattersall, M. (2011). Landscape of cancer clinical trials in Australia: using trial registries to guide future research. Medical Journal of Australia, 194(8), 387-391. [More Information]
  • Simes, R. (2011). Medical Oncology Group of Australia Cancer Achievement Award - Inspirations and influences for a life in clinical trials. Cancer Forum, 35(1), 48-50.
  • Ananda, S., Nowak, A., Cher, L., Dowling, A., Brown, C., Simes, R., Rosenthal, M. (2011). Phase 2 trial of temozolomide and pegylated liposomal doxorubicin in the treatment of patients with glioblastoma multiforme following concurrent radiotherapy and chemotherapy. Journal of Clinical Neuroscience, 18(11), 1444-1448. [More Information]
  • Lee, C., Simes, R., Brown, C., Lord, S., Wagner, U., Plante, M., Vergote, I., Pisano, C., Parma, G., Burges, A., Gebski, V., et al (2011). Prognostic nomogram to predict progression-free survival in patients with platinum-sensitive recurrent ovarian cancer. British Journal of Cancer, 105(8), 1144-1150. [More Information]
  • Cox, K., Goel, S., O'Connell, R., Boyer, M., Beale, P., Simes, R., Stockler, M. (2011). Randomized cross-over trial comparing inpatient and outpatient administration of high-dose cisplatin. Internal Medicine Journal, 41(2), 172-178. [More Information]
  • Tebbutt, N., Murphy, F., Zannino, D., Wilson, C., Cummins, M., Abdi, E., Strickland, A., Lowenthal, R., Marx, G., Karapetis, C., Shannon, J., Simes, R., et al (2011). Risk of arterial thromboembolic events in patients with advanced colorectal cancer receiving bevacizumab. Annals of Oncology, 22(8), 1834-1838. [More Information]
  • Farrar, D., Duley, L., Burls, A., Dorling, J., Embleton, N., McGuire, W., Oddie, S., Simes, R., Tarnow-Mordi, W., Thornton, J., et al (2011). Rushing to clamp umbilical cord: More evidence is needed to inform practice. BMJ: British Medical Journal, 342(Letters), d122-d122. [More Information]
  • Clarke, S., Yip, S., Brown, C., van Hazel, G., Ransom, D., Goldstein, D., Jeffrey, G., Tebbutt, N., Buck, M., Lowenthal, R., Boland, A., Gebski, V., Simes, R., et al (2011). Single-agent irinotecan or 5-fluorouracil and leucovorin (FOLFIRI) as second-line chemotherapy for advanced colorectal cancer; results of a randomised phase II study (DaVINCI) and meta-analysis. European Journal of Cancer, 47(12), 1826-1836. [More Information]
  • Sjoquist, K., Burmeister, B., Smithers, B., Zalcberg, J., Simes, R., Barbour, A., Gebski, V. (2011). Survival after neoadjuvant chemotherapy or chemoradiotherapy for resectable oesophageal carcinoma: an updated meta-analysis. The Lancet Oncology, 12(7), 681-692. [More Information]

2010

  • Simes, R., Voysey, M., O'Connell, R., Glasziou, P., Best, J., Scott, R., Pardy, C., Byth Wilson, K., Sullivan, D., Ehnholm, C., Keech, A. (2010). A novel method to adjust efficacy estimates for uptake of other active treatments in long-term clinical trials. PloS One, 5(1), e8580-1-e8580-10. [More Information]
  • Taskinen, M., Barter, P., Ehnholm, C., Sullivan, D., Mann, K., Simes, R., Best, J., Hamwood, S., Keech, A. (2010). Ability of traditional lipid ratios and apolipoprotein ratios to predict cardiovascular risk in people with type 2 diabetes. Diabetologia, 53(9), 1846-1855. [More Information]
  • De Roock, W., Jonker, D., Di Nicolantonio, F., Sartore-Bianchi, A., Tu, D., Siena, S., Lamba, S., Arena, S., Frattini, M., Piessevaux, H., Simes, R., et al (2010). Association of KRAS p.G13D Mutation With Outcome in Patients With Chemotherapy-Refractory Metastatic Colorectal Cancer Treated With Cetuximab. JAMA: The Journal of the American Medical Association, 304(16), 1812-1820. [More Information]
  • Tebbutt, N., Wilson, K., Gebski, V., Cummins, M., Zannino, D., van Hazel, G., Robinson, B., Broad, A., Ganju, V., Ackland, S., Stockler, M., Simes, R., et al (2010). Capecitabine, Bevacizumab and Mitomycin in First-Line Treatment of Metastatic Colorectal Cancer: Results of the Australasian Gastrointestinal Trials Group Randomized, Phase III MAX Study. Journal of Clinical Oncology, 28(19), 3191-3198. [More Information]
  • Van Glabbeke, M., Verweij, J., Blay, J., Debiec-Rychter, M., Demetri, G., Heinrich, M., Borden, E., Blanke, C., Crowley, J., Rankin, C., Zalcberg, J., Simes, R., et al (2010). Comparison of Two Doses of Imatinib for the Treatment of Unresectable or Metastatic Gastrointestinal Stromal Tumors: A Meta-Analysis of 1,640 Patients. Journal of Clinical Oncology, 28(7), 1247-1253. [More Information]
  • Grimison, P., Stockler, M., Thomson, D., Olver, I., Harvey, V., Gebski, V., Lewis, C., Levi, J., Boyer, M., Gurney, H., Boland, A., Simes, R., et al (2010). Comparison of Two Standard Chemotherapy Regimens for Good-Prognosis Germ Cell Tumors: Updated Analysis of a Randomized Trial. Journal of the National Cancer Institute, 102(16), 1253-1262. [More Information]
  • Davis, T., Ting, R., Best, J., Donoghoe, M., Drury, P., Sullivan, D., Jenkins, A., O'Connell, R., Whiting, M., Glasziou, P., Simes, R., Gebski, V., Keech, A., et al (2010). Effects of fenofibrate on renal function in patients with type 2 diabetes mellitus: the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) Study. Diabetologia, 54(2), 280-290. [More Information]
  • Baigent, C., Blackwell, L., Emberson, J., Holland, L., Reith, C., Bhala, N., Peto, R., Barnes, E., Keech, A., Simes, R., et al (2010). Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170 000 participants in 26 randomised trials. The Lancet, 376(9753), 1670-1681. [More Information]
  • Lee, C., Lord, S., Stockler, M., Coates, A., Gebski, V., Simes, R. (2010). Historical cross-trial comparisons for competing treatments in advanced breast cancer - An empirical analysis of bias. European Journal of Cancer, 46(3), 541-548. [More Information]
  • de Boer, S., Westerhout, C., Simes, R., Granger, C., Zijlstra, F., Boersma, E. (2010). Mortality and Morbidity Reduction by Primary Percutaneous Coronary Intervention Is Independent of the Patient's Age. J A C C: Cardiovascular Interventions, 3(3), 324-331. [More Information]
  • Lee, C., Stockler, M., Coates, A., Gebski, V., Lord, S., Simes, R. (2010). Self-reported health-related quality of life is an independent predictor of chemotherapy treatment benefit and toxicity in women with advanced breast cancer. British Journal of Cancer, 102(9), 1341-1347. [More Information]
  • Cui, J., Forbes, A., Kirby, A., Marschner, C., Simes, R., Hunt, D., West, M., Tonkin, A. (2010). Semi-parametric risk prediction models for recurrent cardiovascular events in the LIPID study. BMC Medical Research Methodology, 10(27), 27-1-27-9. [More Information]
  • Askie, L., Baur, L., Campbell, K., Daniels, L., Hesketh, K., Magarey, A., Mihrshahi, S., Rissel, C., Simes, R., Taylor, B., Voysey, M., et al (2010). The Early Prevention of Obesity in CHildren (EPOCH) Collaboration - an Individual Patient Data Prospective Meta-Analysis. BMC Public Health, 10, 728-1-728-8. [More Information]
  • Califf, R., Armstrong, P., Granger, C., Harrington, R., Lee, K., Simes, R., van de Werf, F., Wallentin, L., White, H. (2010). Towards a new order in cardiovascular medicine: re-engineering through global collaboration. European Heart Journal, 31(8), 911-917. [More Information]
  • Simes, R., O'Connell, R., Aylward, P., Varshavsky, S., Diaz, R., Wilcox, R., Armstrong, P., Granger, C., French, J., Van de Werf, F., Marschner, C., et al (2010). Unexplained international differences in clinical outcomes after acute myocardial infarction and fibrinolytic therapy: Lessons from the Hirulog and Early Reperfusion or Occlusion (HERO)-2 trial. American Heart Journal, 159(6), 988-997. [More Information]

2009

  • Grimison, P., Simes, R., Hudson, M., Stockler, M. (2009). Deriving a Patient-Based Utility Index from a Cancer-Specific Quality of Life Questionnaire. Value in Health, 12(5), 800-807. [More Information]
  • Cui, J., Forbes, A., Kirby, A., Simes, R., Tonkin, A. (2009). Laboratory and non-laboratory-based risk prediction models for secondary prevention of cardiovascular disease: the LIPID study. European Journal of Cardiovascular Prevention and Rehabilitation, 16(6), 660-668. [More Information]
  • Soderberg, S., Colquhoun, D., Keech, A., Yallop, J., Barnes, E., Pollicino, C., Simes, R., Tonkin, A., Nestel, P. (2009). Leptin, but not adiponectin, is a predictor of recurrent cardiovascular events in men: results from the LIPID study. International Journal of Obesity, 33(1), 123-130. [More Information]
  • Lee, C., Lord, S., Coates, A., Simes, R. (2009). Molecular biomarkers to individualise treatment: assessing the evidence. Medical Journal of Australia, 190(11), 631-636. [More Information]
  • Grimison, P., Simes, R., Hudson, M., Stockler, M. (2009). Preliminary Validation of an Optimally Weighted Patient-Based Utility Index by Application to Randomized Trials in Breast Cancer. Value in Health, 12(6), 967-976. [More Information]
  • Mittman, N., Au, H., Tu, D., O'Callaghan, C., Isogai, P., Karapetis, C., Zalcberg, J., Evans, W., Moore, M., Siddiqui, J., Simes, R., Tebbutt, N., et al (2009). Prospective Cost-Effectiveness Analysis of Cetuximab in Metastatic Colorectal Cancer: Evaluation of National Cancer Institute of Canada Clinical Trials Group CO.17 Trial. Journal of the National Cancer Institute, 101(17), 1182-1192. [More Information]
  • Taskinen, M., Sullivan, D., Ehnholm, C., Whiting, M., Zannino, D., Simes, R., Keech, A., Barter, P. (2009). Relationships of HDL cholesterol, ApoA-I, and ApoA-II with homocysteine and creatinine in patients with Type 2 diabetes treated with fenofibrate. Arteriosclerosis, Thrombosis, and Vascular Biology, 29(6), 950-955. [More Information]
  • Gill, G., Wetzig, N., Gebski, V., Stockler, M., Ung, O., Campbell, I., Simes, R. (2009). Sentinel-Lymph-Node-Based Management or Routine Axillary Clearance? One-Year Outcomes of Sentinel Node Biopsy Versus Axillary Clearance (SNAC): A Randomized Controlled Surgical Trial. Annals of Surgical Oncology, 16(2), 266-275. [More Information]
  • Berger, J., Elliott, L., Gallup, D., Roe, M., Granger, C., Armstrong, P., Simes, R., White, H., Van de Werf, F., Topol, E., et al (2009). Sex Differences in Mortality Following Acute Coronary Syndromes. JAMA: The Journal of the American Medical Association, 302(8), 874-882. [More Information]
  • Carrick, S., Parker, S., Thornton, C., Ghersi, D., Simes, R., Wilcken, N. (2009). Single agent versus combination chemotherapy for metastatic breast cancer. Cochrane Database of Systematic Reviews, (2), CD003372-1-CD003372-109. [More Information]
  • Clarke, P., Hayes, A., Glasziou, P., Scott, R., Simes, R., Keech, A. (2009). Using the EQ-5D index score as a predictor of outcomes in patients with type 2 diabetes. Medical Care, 47(1), 61-68. [More Information]

2008

  • Hayes, A., Clarke, P., Glasziou, P., Simes, R., Drury, P., Keech, A. (2008). Can self-rated health scores be used for risk prediction in patients with type 2 diabetes? Diabetes Care, 31(4), 795-797. [More Information]
  • Smith, M., Gill, P., Wetzig, N., Sourjina, T., Gebski, V., Ung, O., Campbell, I., Kollias, J., Coskinas, X., Macphee, A., Simes, R., Stockler, M., et al (2008). Comparing patients' and clinicians' assessment of outcomes in a randomised trial of sentinel node biopsy for breast cancer (the RACS SNAC trial). Breast Cancer Research and Treatment, Online (117)((1)), 1 (99)-11 (109). [More Information]
  • Duric, V., Butow, P., Sharpe, L., Heritier, S., Boyle, F., Beith, J., Wilcken, N., Coates, A., Simes, R., Stockler, M. (2008). Comparing patients' and their partners' preferences for adjuvant chemotherapy in early breast cancer. Patient Education and Counseling, 72(2), 239-245. [More Information]
  • Stewart, R., North, F., Sharples, K., Simes, R., Tonkin, A., White, H. (2008). Differences in cardiovascular mortality between Australia and New Zealand according to socioeconomic status: findings from the Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study. New Zealand Medical Journal, 121(1269), 11-23.
  • Kearney, P., Blackwell, L., Collins, R., Keech, A., Simes, R., Peto, R., Armitage, J., Baigent, C. (2008). Efficacy of cholesterol-lowering therapy in 18 686 people with diabetes in 14 randomised trials of statins: a meta-analysis. The Lancet, 371, 117-125. [More Information]
  • Keech, A., Mitchell, P., Summanen, P., Davis, T., Simes, R. (2008). Fenofibrate and diabetic retinopathy - Authors' reply. The Lancet, 371(9614), 722-722.
  • Berger, J., Stebbins, A., Granger, C., Ohman, E., Armstrong, P., Van de Werf, F., White, H., Simes, R., Harrington, R., Califf, R., et al (2008). Initial Aspirin Dose and Outcome Among ST-Elevation Myocardial Infarction Patients Treated With Fibrinolytic Therapy. Circulation (Baltimore), 117(2), 192-199. [More Information]
  • Karapetis, C., Khambata-Ford, S., Jonker, D., O'Callaghan, C., Tu, D., Tebbutt, N., Simes, R., Chalchal, H., Shapiro, J., Robitaille, S., et al (2008). K-ras Mutations and Benefit from Cetuximab in Advanced Colorectal Cancer. New England Journal of Medicine, 359(17), 1757-1765. [More Information]
  • Glasziou, P., Irwig, L., Heritier, S., Simes, R., Tonkin, A. (2008). Monitoring cholesterol levels: Measurement error or true change? Annals of Internal Medicine, 148(9), 656-661. [More Information]
  • Cui, J., Forbes, A., Kirby, A., Marschner, C., Simes, R., West, M., Tonkin, A. (2008). Parametric conditional frailty models for recurrent cardiovascular events in the lipid study. Clinical Trials, 5(6), 565-574. [More Information]
  • Kearney, P., Keech, A., Simes, R., Collins, R. (2008). Statins and diabetes: authors' reply. The Lancet, 371(9626), 1752-1752.
  • Dwan, K., Altman, D., Arnaiz, J., Bloom, J., Chan, A., Cronin, E., Decullier, E., Easterbrook, P., Von Elm, E., Gamble, C., Ghersi, D., Simes, R., et al (2008). Systematic Review of the Empirical Evidence of Study Publication Bias and Outcome Reporting Bias. PloS One, 3(8), e3081-1-e3081-31. [More Information]
  • Lord, S., Lee, C., Simes, R. (2008). The Role of Predictive and Prognostic Markers in Cancer. Cancer Forum, 32(3), 139-142.
  • West, M., Nestel, P., Kirby, A., Schnabel, R., Sullivan, D., Simes, R., Pollicino, C., Lubos, E., Munzel, T., White, H., et al (2008). The value of N-terminal fragment of brain natriuretic peptide and tissue inhibitor of metalloproteinase-1 levels as predictors of cardiovascular outcome in the LIPID study. European Heart Journal, 29(7), 923-931. [More Information]

2007

  • Lord, S., Irwig, L., Simes, R. (2007). A philosophical approach to diagnostic test evaluation - In Response. Annals of Internal Medicine, 146(10), 757-758.
  • Gebski, V., Keech, A., Simes, R. (2007). Applying subgroup analysis to individual patient decisions. In Anthony Keech, Val Gebski, Rhana Pike (Eds.), Interpreting and reporting clinical trials: a guide to the CONSORT statement and the principles of randomised controlled trials, (pp. 114-122). Sydney: AMPCo.
  • Marschner, C., Simes, R., Keech, A. (2007). Biases in the Identification of Risk Factor Thresholds and J-Curves. American Journal of Epidemiology, 166(7), 824-831. [More Information]
  • Smith, M., Gill, P., Wetzig, N., Sourjina, T., Simes, R., Stockler, M. (2007). Bs06 patient-rated outcome measures were more sensitive than clinician-rated measures at distinguishing the effects of sentinel node biopsy and axillary clearance in the snac trial. ANZ Journal of Surgery, 77(Suppl. 1), A2-A2. [More Information]
  • Mark, D., Van de Werf, F., Simes, R., White, H., Wallentin, L., Califf, R., Armstrong, P. (2007). Cardiovascular disease on a global scale: defining the path forward for research and practice. European Heart Journal, 28(21), 2678-2684. [More Information]
  • Jonker, D., O’Callaghan, C., Karapetis, C., Zalcberg, J., Tu, D., Au, H., Berry, S., Krahn, M., Price, T., Simes, R., et al (2007). Cetuximab for the Treatment of Colorectal Cancer. New England Journal of Medicine, 357(20), 2040-2048. [More Information]
  • Grimison, P., Simes, R., Stockler, M. (2007). Development and validation of optimally weighted measures of global health-related quality of life (QoL) and utility based on a cancer-specific QoL instrument. Value in Health, 10(6), A226-A227.
  • Keech, A., Mitchell, P., Summanen, P., O'Day, J., Davis, T., Moffitt, M., Taskinen, M., Simes, R., Tse, D., Williamson, E., Merrifield, A., O'Connell, R., et al (2007). Effect of fenofibrate on the need for laser treatment for diabetic retinopathy (FIELD study): a randomised controlled trial. The Lancet, 370(9600), 1687-1697. [More Information]
  • Stockler, M., O'Connell, R., Nowak, A., Goldstein, D., Turner, J., Wilcken, N., Wyld, D., Abdi, E., Glasgow, A., Beale, P., Dhillon, H., Heritier, S., Carter, C., Hickie, I., Simes, R., et al (2007). Effect of sertraline on symptoms and survival in patients with advanced cancer, but without major depression: a placebo-controlled double-blind randomised trial. Lancet Oncology, 8(7), 603-612. [More Information]
  • Timmer, J., Ottervanger, J., de Boer, M., Boersma, E., Grines, C., Westerhout, C., Simes, R., Granger, C., Zijlstra, F., Primary Coronary Angioplasty vs Thrombolysis–2 Trialists, C. (2007). Primary percutaneous coronary intervention compared with fibrinolysis for myocardial infarction in diabetes mellitus: results from the Primary Coronary Angioplasty vs Thrombolysis-2 trial. Archives of Internal Medicine, 167(13), 1353-1359. [More Information]
  • Duric, V., Butow, P., Sharpe, L., Boyle, F., Beith, J., Wilcken, N., Heritier, S., Coates, A., Simes, R., Stockler, M. (2007). Psychosocial factors and patients' preferences for adjuvant chemotherapy in early breast cancer. Psycho-Oncology: journal of the psychological, social and behavioral dimensions of cancer, 16(1), 48-59. [More Information]
  • Gebski, V., Burmeister, B., Smithers, B., Foo, K., Zalcberg, J., Simes, R. (2007). Survival benefits from neoadjuvant chemoradiotherapy or chemotherapy in oesophageal carcinoma: a meta-analysis. Lancet Oncology, 8(3), 226-234. [More Information]
  • Edmond, J., French, J., Aylward, P., Wong, C., Stewart, R., Williams, B., de Pasquale, C., O'Connell, R., van den Berg, K., Van de Werf, F., Simes, R., et al (2007). Variations in the use of emergency PCI for the treatment of re-infarction following intravenous fibrinolytic therapy: impact on outcomes in HERO-2. European Heart Journal, 28(12), 1418-1424. [More Information]

2006

  • Stockler, M., Sourjina, T., Harvey, V., Frances, P., Byrne, M., van Hazel, G., Fitzharris, B., Ackland, S., Finch, K., Lindsay, D., Gebski, V., Simes, R., Coates, A., et al (2006). A randomized trial of capecitabine given intermittently versus continuously versus classical CMF as first line chemotherapy for women with advanced breast cancer unsuited to more intensive treatment. Breast Cancer Research and Treatment, 100(Supplement 1), S278-S278.
  • Keech, A., Simes, R. (2006). Clinical trial design & management: The role of PPAR-ALPHA agonists in prevention of CVD. Atherosclerosis Supplements, 7(3), 174-174.
  • Keech, A., Simes, R., Barter, P., Best, J., Scott, R., Taskinen, M. (2006). Correction to the FIELD study report. The Lancet, 368(9545), 1415. [More Information]
  • Tonkin, A., Eckermann, S., White, H., Friedlander, D., Glasziou, P., Magnus, P., Kirby, A., Mulray, S., Denton, M., Sallaberger, M., Simes, R., et al (2006). Cost-effectiveness of cholesterol-lowering therapy with pravastatin in patients with previous acute coronary syndromes aged 65 to 74 years compared with younger patients: results from the LIPID study. American Heart Journal, 151(6), 1305-1312. [More Information]
  • Stockler, M., Tattersall, M., Boyer, M., Clarke, S., Beale, P., Simes, R. (2006). Disarming the guarded prognosis: predicting survival in newly referred patients with incurable cancer. British Journal of Cancer, 94(2), 208-212. [More Information]
  • Boersma, E., Westerhout, C., Simes, R., Weaver, W., Andersen, H., Armstrong, P., Granger, C., Grines, C., Zijlstra, F., Widimsky, P., et al (2006). Does time matter? A pooled analysis of randomized clinical trials comparing primary percutaneous coronary intervention and in-hospital fibrinolysis in acute myocardial infarction patients. European Heart Journal, 27(7), 779-788. [More Information]
  • Baigent, C., Keech, A., Kearney, P., Collins, R., Simes, R. (2006). Efficacy and safety of cholesterol-lowering treatment - Reply. The Lancet, 367(9509), 470-471.
  • Baigent, C., Keech, A., Kearney, P., Collins, R., Simes, R. (2006). Efficacy and safety of cholesterol-lowering treatment-authors' reply [letter]. The Lancet, 367(9509), 470-471.
  • Edmond, J., French, J., Stewart, R., Aylward, P., de Pasquale, C., Williams, B., O'Connell, R., Simes, R., White, H. (2006). Frequency of recurrent ST-elevation myocardial infarction after fibrinolytic therapy in a different territory as a manifestation of multiple unstable coronary arterial plaques. The American Journal of Cardiology, 97(7), 947-951. [More Information]
  • Sullivan, D., Forder, P., Simes, R., Whiting, M., Keech, A. (2006). Individual and combined effects of fenofibrate and sulphonylureas on HDL cholesterol and outcomes. XIV International Symposium on Atherosclerosis, Ireland: Elsevier Ireland Ltd.
  • Alexander, K., Newby, L., Bhapkar, M., White, H., Hochman, J., Pfisterer, M., Moliterno, D., Peterson, E., Van de Werf, F., Simes, R., Keech, A., et al (2006). International variation in invasive care of the elderly with acute coronary syndromes. European Heart Journal, 27(13), 1558-1564. [More Information]
  • Tonelli, M., Isles, C., Craven, T., Furberg, C., Tonkin, A., Pfeffer, M., Shepherd, J., Cobbe, S., Sacks, F., Simes, R., et al (2006). Letter regarding article by Tonelli et al, "Effect of pravastatin on rate of kidney function loss in people with or at risk for coronary disease" - Response. Circulation Journal, 113, e59-e60. [More Information]
  • Galbraith, S., Marschner, I., Simes, R. (2006). Missing data methods for the assessment of surrogate outcomes and treatment mechanisms in clinical trial substudies. Statistics in Medicine, 25(3), 415-431. [More Information]
  • Stocker, R., Pollicino, C., Gay, C., Nestel, P., Colquhoun, D., Whiting, M., Tonkin, A., Sullivan, D., Simes, R. (2006). Neither plasma coenzyme Q(10) concentration, nor its decline during pravastatin therapy, is linked to recurrent cardiovascular disease events: A prospective case-control study from the LIPID study. Atherosclerosis, 187(1), 198-204. [More Information]
  • Colquhoun, D., Soderberg, S., Kirby, A., Keech, A., Simes, R., Hague, W., Hamilton-Craig, I., Tonkin, A. (2006). Obesity and adipokines as risk factors for major coronary heart disease events in patients with CHD: Results from the lipid trial. XIV International Symposium on Atherosclerosis, Ireland: Elsevier Ireland Ltd.
  • Orlandini, A., Diaz, R., Wojdyla, D., Pieper, K., Van de Werf, F., Granger, C., Harrington, R., Boersma, E., Califf, R., Armstrong, P., Simes, R., et al (2006). Outcomes of patients in clinical trials with ST-segment elevation myocardial infarction among countries with different gross national incomes. European Heart Journal, 27(5), 527-533. [More Information]
  • Van Glabbeke, M., Verweij, J., Casali, P., Simes, R., Le Cesne, A., Reichardt, P., Issels, R., Judson, I., van Oosterom, A., Blay, J. (2006). Predicting toxicities for patients with advanced gastrointestinal stromal tumours treated with imatinib: a study of the European Organisation for Research and Treatment of Cancer, the Italian Sarcoma Group, and the Australasian Gastro-Intestinal Trials Gr. European Journal of Cancer, 42(14), 2277-2285. [More Information]
  • Askie, L., Ghersi, D., Simes, R. (2006). Prospective registration of clinical trials (editorial). Australian Journal of Physiotherapy, 52(4), 237-239.
  • Askie, L., Ghersi, D., Simes, R. (2006). Prospective registration of clinical trials [Editorial]. Australian Journal of Physiotherapy, 52(4), 237-239. [More Information]
  • Gill, P., Gebski, V., Wetzig, N., Ung, O., Campbell, I., Collins, J., Sourjina, T., Coskinas, X., Stockler, M., Simes, R. (2006). Sentinel node (SN) based management causes less arm swelling and better quality of life than routine axillary clearance (AC): 1 year outcomes of the SNAC trial. Breast Cancer Research and Treatment, 100(Supplement 1), S14-S14.
  • Bushnell, C., Griffin, J., Newby, L., Goldstein, L., Mahaffey, K., Graffagnino, C., Harrington, R., White, H., Simes, R., Califf, R., et al (2006). Statin use and sex-specific stroke outcomes in patients with vascular disease. Stroke: a journal of cerebral circulation, 37(6), 1427-1431.
  • Gebski, V., Lagleva, M., Keech, A., Simes, R., Langlands, A. (2006). Survival Effects of Postmastectomy Adjuvant Radiation Therapy Using Biologically Equivalent Doses: A Clinical Perspective - [Response]. Journal of the National Cancer Institute, 98(17), 1021-1022.
  • Gebski, V., Lagleva, M., Keech, A., Simes, R., Langlands, A. (2006). Survival effects of postmastectomy adjuvant radiation therapy using biologically equivalent doses: a clinical perspective. Journal of the National Cancer Institute, 98(1), 26-38. [More Information]
  • Keech, A., Simes, R., Barter, P., Best, J., Scott, R., Taskinen, M. (2006). The FIELD study - Reply. The Lancet, 367(9517), 1142-1143.
  • Lord, S., Irwig, L., Simes, R. (2006). When is measuring sensitivity and specificity sufficient to evaluate a diagnostic test, and when do we need randomized trials? Annals of Internal Medicine, 144(11), 850-855. [More Information]

2005

  • Ackland, S., Jones, M., Tu, D., Simes, R., Yuen, J., Sargeant, A., Dhillon, H., Goldberg, R., Abdi, E., Moore, M., et al (2005). A meta-analysis of two randomised trials of early chemotherapy in asymptomatic metastatic colorectal cancer. British Journal of Cancer, 93(11), 1236-1243. [More Information]
  • O'Connell, R., Edmond, J., French, J., Aylward, P., Simes, R., White, H. (2005). A simple prognostic score for the re-infarction risk following fibrinolytic therapy for myocardial infarction - data from HERO-2. European Heart Journal, 26(Suppl 1), 561-561.
  • Ghersi, D., Wilcken, N., Simes, R. (2005). A systematic review of taxane-containing regimens for metastatic breast cancer. British Journal of Cancer, 93(3), 293-301. [More Information]
  • Gebski, V., Lagleva, M., Simes, R., Keech, A., Langlands, A. (2005). Adjuvant Radiotherapy in Early Breast Cancer: The Clinical Utility of Published Meta-Analysis. RANZCR, 55th Annual Scientific Meeting.
  • West, M., Blankenberg, S., Simes, R., Pollicino, C., Kirby, A., Nestel, P., White, H., Tonkin, A. (2005). Brain natriuretic peptide: a predictor of cardiovascular outcome in the Long-term Intervention with Pravastatin in Ischaemic Disease (LIPID) study. European Heart Journal, 26(Suppl 1), 718-718.
  • Duric, V., Stockler, M., Butow, P., Sharpe, L., Heritier, S., Beith, J., Boyle, F., Wilcken, N., Coates, A., Simes, R. (2005). Comparing patients' and their partners' preferences for adjuvant chemotherapy (ACT) in early breast cancer (EBC). Journal of Clinical Oncology, 23(16S), 546S-546S.
  • Gebski, V., Heritier, S., Pillai, A., Luke, V., Simes, R., Keech, A. (2005). Computer modelling of adaptive randomisation schemes in large scale randomised controlled trials. 20th International Workshop on Statistical Modelling, Sydney, Australia: University of Western Sydney.
  • Sinnaeve, P., Simes, R., Yusuf, S., Garg, J., Mehta, S., Eikelboom, J., Bittl, J., Serruys, P., Topol, E., Granger, C. (2005). Direct thrombin inhibitors in acute coronary syndromes: effect in patients undergoing early percutaneous coronary intervention. European Heart Journal, 26(22), 2396-403. [More Information]
  • Tonelli, M., Keech, A., Shepherd, J., Sacks, F., Tonkin, A., Packard, C., Pfeffer, M., Simes, R., Isles, C., Furberg, C., et al (2005). Effect of pravastatin in people with chronic kidney disease and diabetes mellitus. Hypertension, 46(4), 900-901.
  • Tonelli, M., Keech, A., Shepherd, J., Sacks, F., Tonkin, A., Packard, C., Pfeffer, M., Simes, R., Isles, C., Furberg, C., et al (2005). Effect of pravastatin in people with diabetes and chronic kidney disease. Journal of the American Society of Nephrology, 16(12), 3748-3754. [More Information]
  • Tonelli, M., Isles, C., Craven, T., Tonkin, A., Pfeffer, M., Shepherd, J., Sacks, F., Furberg, C., Cobbe, S., Simes, R., et al (2005). Effect of pravastatin on rate of kidney function loss in people with or at risk for coronary disease. Circulation, 112(2), 171-178. [More Information]
  • Keech, A., Simes, R., Barter, P., Best, J., Scott, R., Taskinen, M., Forder, P., Pillai, A., Davis, T., Glasziou, P., Sullivan, D., MacMahon, S., et al (2005). Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. The Lancet, 366(9500), 1849. [More Information]
  • Baigent, C., Keech, A., Kearney, P., Blackwell, L., Buck, G., Pollicino, C., Kirby, A., Sourjina, T., Peto, R., Collins, R., Simes, R. (2005). Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. The Lancet, 366(9493), 1267-1278. [More Information]
  • Scott, R., Best, J., Forder, P., Taskinen, M., Simes, R., Barter, P., Keech, A. (2005). Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study: baseline characteristics and short-term effects of fenofibrate (ISRCTN64783481). Cardiovascular Diabetology, 4(13), 1-9. [More Information]
  • Armstrong, P., Newby, L., Granger, C., Lee, K., Califf, R., Simes, R., Van de Werf, F., White, H. (2005). Letter regarding article by Armstrong et al, "Lessons learned from a clinical trial" - Response. Circulation (Baltimore), 111(23), e393-e393.
  • Labinaz, M., Mathias, J., Pieper, K., Granger, C., Lincoff, A., Moliterno, D., Van de Werf, F., Simes, R., White, H., Simoons, M., et al (2005). Outcomes of patients with acute coronary syndromes and prior percutaneous coronary intervention: a pooled analysis of three randomized clinical trials. European Heart Journal, 26(2), 128-136. [More Information]
  • Wong, C., French, J., Aylward, P., Stewart, R., Gao, W., Van de Werf, F., Armstrong, P., Simes, R., Raffel, O., Granger, C., et al (2005). Patients With Prolonged Ischemic Chest Pain and Presumed-New Left Bundle Branch Block Have Heterogeneous Outcomes Depending on the Presence of ST-Segment Changes. Journal of the American College of Cardiology, 46(1), 29-38. [More Information]
  • Duric, V., Stockler, M., Heritier, S., Boyle, F., Beith, J., Sullivan, A., Wilcken, N., Coates, A., Simes, R. (2005). Patients' preferences for adjuvant chemotherapy in early breast cancer: what makes AC and CMF worthwhile now? Annals of Oncology, 16(11), 1786-1794. [More Information]
  • Nestel, P., Baghurst, K., Colquhoun, D., Simes, R., Mehalski, K., White, H., Tonkin, A., Kirby, A., Pollicino, C. (2005). Relation of diet to cardiovascular disease risk factors in subjects with cardiovascular disease in Australia and New Zealand: analysis of the Long-Term Intervention with Pravastatin in Ischaemic Disease trial. American Journal of Clinical Nutrition, 81(6), 1322-1329. [More Information]
  • Carrick, S., Parker, S., Thornton, C., Ghersi, D., Simes, R., Wilcken, N. (2005). Single agent versus combination chemotherapy for metastatic breast cancer (Review). Cochrane Database of Systematic Reviews, 2005 (2), 1-22. [More Information]
  • Burmeister, B., Smithers, B., Gebski, V., Fitzgerald, L., Simes, R., Devitt, P., Ackland, S., Gotley, D., Joseph, D., Millar, J., Walpole, E., et al (2005). Surgery alone versus chemoradiotherapy followed by surgery for resectable cancer of the oesophagus: a randomised controlled phase III trial. Lancet Oncology, 6(9), 659-668. [More Information]
  • Ghersi, D., Wilcken, N., Simes, R., Donoghue, E. (2005). Taxane containing regimens for metastatic breast cancer (Review). Cochrane Database of Systematic Reviews, 2005 (2), 1-119. [More Information]
  • Nestel, P., Blankenberg, S., Simes, R., Kirby, A., Tonkin, A. (2005). Tissue inhibitor of metalloproteinase (TIMP-1) is a predictor of recurrent cardiovascular events in the LIPID study. European Heart Journal, 26(Suppl 1), 257-257.
  • Stewart, R., White, H., Kirby, A., Heritier, S., Simes, R., Nestel, P., West, M., Colquhoun, D., Tonkin, A. (2005). White Blood Cell Count Predicts Reduction in Coronary Heart Disease Mortality With Pravastatin. Circulation, 111(14), 1756-1762. [More Information]

2004

  • Cox, K., O'Connell, R., Stockler, M., Boyer, M., Beale, P., Simes, R. (2004). A randomized crossover trial of giving high-dose cisplatin with or without an overnight stay in hospital: Patients' preferences, quality of life, safety and resource use. Journal of Clinical Oncology, 22(14S), 547S-547S.
  • Lord, S., Ghersi, D., Gattellari, M., Wilcken, N., Thornton, C., Simes, J. (2004). Antitumour Antibiotic Containing Regimens For Metastatic Breast Cancer. Cochrane Database of Systematic Reviews, 4(CD003367), 1-123.
  • Boersma, E., Simes, R., Grines, C., Westerhout, C. (2004). Does time matter? Individual patient data-based meta-analysis of primary PCI versus fibrinolysis in acute myocardial infarction randomized trials. Circulation, 110(Suppl III), III 539-III 539.
  • Colquhoun, D., Keech, A., Hunt, D., Marschner, C., Simes, R., Glasziou, P., White, H., Barter, P., Tonkin, A. (2004). Effects Of Pravastatin On Coronary Events In 2073 Patients With Low Levels Of Both Low-Density Lipoprotein Cholesterol And High-Density Lipoprotein Cholesterol: Results From The Lipid Study. European Heart Journal, 25(9), 771-777. [More Information]
  • Kassem-Moussa, H., Mahaffey, K., Graffagnino, C., Tassisa, G., Sila, C., Simes, R., White, H., Califf, R., Bhapkar, M., Newby, L. (2004). Incidence and characteristics of stroke during 90-day follow-up in patients stabilized after an acute coronary syndrome. American Heart Journal, 148(3), 439-446. [More Information]
  • Armstrong, P., Newby, L., Granger, C., Lee, K., Simes, R., Van de Werf, F., White, H., Califf, R. (2004). Lessons learned from a clinical trial. Circulation (Baltimore), 110(23), 3610-3614.
  • Carrick, S., Ghersi, D., Wilcken, N., Simes, R. (2004). Platinum Containing Regimens For Metastatic Breast Cancer. Cochrane Database of Systematic Reviews, 2(CD003374), 1-74.
  • Duric, V., Stockler, M., Butow, P., Sharpe, L., Beith, J., Sullivan, A., Boyle, F., Dhillon, H., Coates, A., Simes, R. (2004). Predictors of the benefits women consider necessary to make adjuvant chemotherapy (ACT) worthwhile for early breast cancer (EBC). Journal of Clinical Oncology, 22(14S), 73S-73S.
  • Kandzari, D., Granger, C., Simoons, M., White, H., Simes, R., Mahaffey, K., Gore, J., Weaver, W., Longstreth, W., Stebbins, A., et al (2004). Risk Factors For Intracranial Hemorrhage And Nonhemorrhagic Stroke After Fibrinolytic Therapy (From The Gusto-I Trial). The American Journal of Cardiology, 93(4), 458-461. [More Information]
  • Keech, A., Best, J., Scott, R., Barter, P., Simes, R., Forder, P., Taskinen, M., FIELD study investigators, F. (2004). Significant lipid changes in a large-scale trial of fenofibrate to prevent cardiovascular disease in type 2 diabetes. Journal of the American College of Cardiology, 43(5), A462-A462.
  • Simes, R., Gebski, V., Keech, A. (2004). Subgroup analysis: application to individual patient decisions. Medical Journal of Australia, 180(9), 467-469. [More Information]
  • Barter, P., Best, J., Colman, P., D'Emden, M., Davis, T., Drury, P., Ehnholm, C., Glasziou, P., Hunt, D., Keech, A., Forder, P., Simes, R., et al (2004). The need for a large-scale trial of fibrate therapy in diabetes: the rationale and design of the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study. Cardiovascular Diabetology, 3(December), 9 - 1-9 - 11.

2003

  • Glare, P., Virik, K., Jones, M., Hudson, M., Eychmuller, S., Simes, R., Christakis, N. (2003). A systematic review of physicians' survival predictions in terminally ill cancer patients. BMJ: British Medical Journal, 327(195), 195-198.
  • Magliano, D., Liew, D., Pater, H., Kirby, A., Hunt, D., Simes, R., Sundararajan, V., Tonkin, A. (2003). Accuracy of the Australian National Death Index: comparison with adjudicated fatal outcomes among Australian participants in the long-term intervention with Pravastatin in Ischaemic Disease (LIPID) Study. Australian and New Zealand Journal of Public Health, 27(6), 649-653. [More Information]
  • Pike, R., Keech, A., Simes, R. (2003). Clinical trials research in the new millennium: the International Clinical Trials Symposium, Sydney, 21-23 October 2002. Medical Journal of Australia, 178(7), 316-317.
  • Stewart, R., North, F., West, T., Sharples, K., Simes, R., Colquhoun, D., White, H., Tonkin, A. (2003). Depression and cardiovascular morbidity and mortality: cause or consequence? European Heart Journal, 24, 2027-2037. [More Information]
  • Hague, W., Forder, P., Simes, R., Hunt, D., Tonkin, A. (2003). Effect of pravastatin on cardiovascular events and mortality in 1516 women with coronary heart disease: Results from the Long-Term Intervention with Pravastatin in Ischemic Disease (LIPID) study. American Heart Journal, 145(4), 643-651.
  • Kramer, J., Newby, L., Chang, W., Simes, R., Van de Werf, F., Granger, C., Lee, K., White, H., Piegas, L., Topol, E., et al (2003). International variation in the use of evidence-based medicines for acute coronary syndromes. European Heart Journal, 24(23), 2133-2141. [More Information]
  • Patel, A., Jones, M., Simes, R., Topol, E., Califf, R., Van, D., Betriu,, A., Ardissino,, D., Armstrong, P., Aylward, P., et al (2003). Primary coronary angioplasty compared with intravenous thrombolytic therapy for acute myocardial infarction: six-month follow up and analysis of individual patient data from randomized trials. American Heart Journal, 145(1), 48-57.
  • Keech, A., Colquhoun, D., Best, J., Kirby, A., Simes, R., Hunt, D., Hague, W., Beller, E., Arulchelvam, M., Baker, J., et al (2003). Secondary prevention of cardio vascular events with long-term Pravastatin in patients with diabetes or impared fasting glucose: results from the LIPID trial. Diabetes Care, 26(10), 2713-2721.
  • Ghersi, D., Wilcken, N., Simes, R., Donoghue, E. (2003). Taxane containing regimes for metastatic breast cancer. Cochrane Database of Systematic Reviews, 168(37), 3117-3120. [More Information]
  • Eckermann, S., Martin, A., Stockler, M., Simes, R. (2003). The benefits and costs of tamoxifen for breast cancer prevention. Australian and New Zealand Journal of Public Health, 27(1), 34-40.

2002

  • Coates, A., Thompson, J., McMullen, A., Simes, R., McCarthy, W., Hersey, P., Sillar, R., Mcleod, R., Gill, P., Coventry, B., Dhillon, H. (2002). Adjuvant Immunotherapy of Patients with High-Risk Melanoma Using Vaccinia Viral Lysates of Melanoma: Results of a Randomized Trial. Journal of Clinical Oncology, 20(20), 4181-4189.
  • Glasziou, P., Eckermann, S., Mulray, S., Simes, R., Martin, A., Kirby, A., Hall, J., White, H., Caleo, S., Tonkin, A. (2002). Cholesterol-lowering therapy with pravastatin in patients with average cholesterol levels and establisheed ischaemic heart disease: is it cost effective? Medical Journal of Australia, 177(8), 428-434.
  • Zijlstra, F., Patel, A., Jones, W., Grines, C., Ellis, S., Garcia, E., Grinfeld, L., Gibbons, R., Ribeiro, E., Ribichini, F., Simes, R., et al (2002). Clinical characteristics and outcome of patients with early(<2h), intermediate (2-4h) and late (>4h) presentation treated by primary coronary angioplasty or thrombolytic therapy for acute myocardial infarction. European Heart Journal, 23(7), 550-557.
  • Simes, R., Furberg, C., Braunwald, E., Davis, B., Ford, I., Tonkin, A., Shepherd, J., Keech, A. (2002). Effects of pravastatin on mortality in patients with and without coronary heart disease across a broad range of cholesterol levels. European Heart Journal, 23(3), 207-215.
  • Cuzick, J., Forbes, J., Edwards, R., Baum, M., Cawthorn, S., Coates, A., Hamed, H., Howell, A., Powels, T., Dhillon, H., Gebski, V., Simes, R. (2002). First results from the International Breast Cancer Intervention Study (IBIS-1): a randomised prevention trial. The Lancet, 360(9336), 817-824.
  • Cuzjik, J., Dhillon, H., Gebski, V., Simes, R. (2002). First results from the International Breast Cancer Intervention Study (IBIS-I): a randomised prevention trial. The Lancet, 360(9336), 817-824.
  • Simes, R., Kirby, A., Keech, A., Hague, W., MacMahon, S., Hunt, D., Tonkin, A., Alyward, P., Colquhoun, D., Glasziou, P., et al (2002). Long-term effectiveness and safety of pravastatin in 9014 patients with coronary heart disease and average cholesterol concentrations: the LIPID trial follow up. The Lancet, 359, 1379-1387.
  • Boersma, E., Harrington, R., Moliterno, D., White, H., Theroux, P., Van de Werf, F., Torbal, A., Armstrong, P., Wallentin, L., Wilcox, R., Simes, R., et al (2002). Platelet glycoprotein IIb/IIIa inhibitors in acute coronary syndromes: a meta-analysis of all major randomised clinical trials. The Lancet, 359(9302), 189-198.
  • Simes, R., Keech, A., et, A. (2002). Randomized, placebo-controlled trial of titrated intravenous lamifiban for acute coronary syndromes. Circulation, 105(3), 316-321.
  • Simes, R., Marschner, C., Hunt, D., Sullivan, D., Colquhoun, D., Hague, W., Stewart, R., Keech, A., Thompson, P., White, H., et al (2002). Relationship between lipid levels and clinical outcomes in the long-term intervention with pravastatin in ischemic disease (LIPID) trial: to what extent is the reduction in coronary events with pravastatin explained by on-study lipid levels? Circulation, 105(10), 1162-1169.
  • West, M., White, H., Simes, R., Kirby, A., Watson, J., Anderson, N., Hankey, G., Simes, S., Hunt, D., Tonkin, A. (2002). Risk factors for non-haemorraghic stroke in patients with coronary heart disease and the effect of lipid-modifying therapy with pravastatin. Journal of Hypertension, 20(12), 2513-2517.
  • Gebski, V., Simes, R. (2002). Survival plots for interpreting trial results. International Clinical Trials Symposium.
  • Al-Khatib, S., Huang, Y., Califf, R., Lee, K., Simoons, M., Van de Werf, F., White, H., Simes, R., Granger, C., Armstrong, P., et al (2002). Sustained ventricular arrythmias among patients with acute coronary syndromes with no ST-segment elevation: incidence, predictors and outcomes. Circulation, 106(3), 309-312.
  • Armstrong, P., Newby, L., Califf, R., White, H., Harrington, R., Van de Werf, F., Granger, C., Simes, R., Hasselblad, V. (2002). The failure of orally administered glycoprotein IIb/IIIa inhibitors to prevent recurrent cardiac events. The American Journal of Medicine, 112(8), 647-658.

2001

  • Ghersi, D., Simes, R., Stockler, M., Tattersall, M., Wilcken, N., Henderson, I., Basser, R., Brunswick, C., Fossati, C., Liberati, A., et al (2001). Addition of drug/s to a chemotherapy regimen for metastatic breast cancer [protocol]. Cochrane Database of Systematic Reviews, Issue 4, 1-4.
  • Ghersi, D., Simes, R., Stockler, M., Tattersall, M., Wilcken, N., Basser, R., Henderson, I., Brunswick, C., Fossati, R., Liberati, A., et al (2001). Antitumor antibiotic containing regimins for metastatic breast cancer [protocol]. Cochrane Database of Systematic Reviews, Issue 4, 1-4.
  • Hunt, D., Young, P., Simes, R., Hague, W., Mann, S., Owensby, D., Lane, G., Tonkin, A. (2001). Benefits of pravastatin on cardiovascular events and mortality in older patients with coronary heart disease are equal to or exceed those seen in younger patients. Annals of Internal Medicine, (134), 931-940.
  • Simes, R., Hague, W., Young, P., Hunt, D., Mann, S., Owensby, D., Lande,, G., Tonkin, A. (2001). Benefits of pravastatin on cardiovascular events and mortalty in older patients with coronary heart disease are equpal to or exceed those seen isn younder patients: results from LIPID Trial. Annals of Internal Medicine, 134 (10), 931-940.
  • Lumley, T., Simes, R., Gebski, V., Hudson, H. (2001). Combining components of quality of life to increase precision and evaluate trade-offs. Statistics in Medicine, 20(21), 3231-3249.
  • Lumley, T., Simes, R., Gebski, V., Hudson, M. (2001). Combining components of quality of life to increase precision and evaluate trade-offs. Statistics in Medicine, 20, 3231-3249.
  • Toner, G., Stockler, M., Boyer, M., Jones, M., Thomson, D., Harvey, V., Olver, I., Dhillon, H., McMullen, A., Gebski, V., Levi, J., Simes, R. (2001). Comparison of two standard chemotherapy regimens for good-prognosis germ-cell tumours: a randomised trial. The Lancet, 357(9528), 739-745.
  • Jeffery, H., Simes, R., Lawrence, G., Tudehope, D., Baumann,, K., Gill, A., Cole, M., Drew, J., McPhee,, A., Ratcliffe, J., et al (2001). Enteral human IgG for prevention of necrotising enterocolitis: a placebo-controlled, randomised trial. The Lancet, 357, 2090-2094.
  • Gebski, V., Veness, M., Simes, R., Shakespeare, T. (2001). Improving interpretation of clinical studies by use of confidence intervals, clinical significnce cureves, and risk analysis. The Lancet, 357, 1349-1353.
  • Shakespeare, T., Gebski, V., Veness, M., Simes, R. (2001). Improving interpretation of clinical studies by use of confidence levels, clinical significance curves, and risk-benefit contours. The Lancet, 357(9265), 1349-1353.
  • Ghersi, D., Simes, R., Stockler, M., Tattersall, M., Wilcken, N., Henderson, I., Basser, R., Brunswick, C., Fossati, R., Liberati, A., et al (2001). Larger vs smaller dose of the same drug/s regimen for metastatic breast cancer [protocol]. Cochrane Database of Systematic Reviews, Issue 4, 1-4.
  • Marschner, C., Simes, R., Colquhoun, D., Glasziou, P., Harris, P., Singh, B., Friedlander, D., White, H., Thompson, P., Tonkin, A. (2001). Long-term risk stratification for survivors of acute coronary syndromes. Journal of the American College of Cardiology, 38(1), 56-63.
  • Simes, R., Coates, A. (2001). Patient preferences for adjuvant chemotherapy of early breast cancer: How much benefit is needed? Journal of the National Cancer Institute, 30, 146-152.
  • Ghersi, D., Simes, R., Stockler, M., Tattersall, M., Wilcken, N., Henderson, I., Basser, R., Brunswick, C., Fossati, R., Liberati, A., et al (2001). Platinum containing reimens for metastatic breast cancer [protocol]. Cochrane Database of Systematic Reviews, Issue 4, 1-4.
  • Ghersi, D., Simes, R., Stockler, M., Tattersall, M., Wilcken, N., Henderson, I., Basser, R., Brunswick, C., Fossati, R., Liberati, A., et al (2001). Single agent vs combination chemotherapy for metastatic breast cancer [protocol]. Cochrane Database of Systematic Reviews, Issue 4, 1-4.
  • Ghersi, D., Simes, R., Stockler, M., Tattersall, M., Wilcken, N., Henderson, I., Basser, R., Brunswick, C., Fossati, C., Liberati, A., et al (2001). Taxane containing regimens for metastatsic breast cancer [protocol]. Cochrane Database of Systematic Reviews, Issue 4, 1-4.
  • Ghersi, D., Simes, R., Stockler, M., Tattersall, M., Wilcken, N., Henderson, I., Basser, R., Brunswick, C., Fossati, R., Liberati, A., et al (2001). Two drug combinations vs combinations of 3 or more cytotoxic drugs for meastatic brest cancer [protocol]. Cochrane Database of Systematic Reviews, Issue 4, 1-4.

2000

  • Stockler, M., Wilcken, N., Ghersi, D., Simes, R. (2000). Systematic reviews of chemotherapy and endocrine therapy in metastatic breast cancer. Cancer Treatment Reviews, 26(3), 151-168.

To update your profile click here. For support on your academic profile contact .